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1The research work incorporated in the thesis with the title “SEARCHING NEW
HETEROCYCLIC ENTITIES OF PHARMACEUTICAL IMPORTANCE” has
been described as under.
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON TRIAZOLES
[C] STUDIES ON MICROWAVE INDUCED SYNTHESIS
OF 5,6- DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES
[A] STUDIES ON PYRAZOLES
We are engaged in a programme to explore novel heterocyclic entities in order to
study their pharmacological profile. Our efforts are focused on introduction of chemical
diversity in the molecular frame work in order to synthesizing active molecules of widely
different composition.
Pyrazole derivatives are associated with broad spectrum of  pharmacological
activities such as antimicrobial, antitubercular, antiinflammatory, antiarthritic,  plant growth
regulator, anticonvulsant, antitumor, hypnotic and  also used as insecticidal and
herbicidal.
Prompted by these facts, we have designed and synthesized some novel
chalcones, pyrazolines, cyanopyridones, isoxazoles, imidazolinones, acetonitriles and
thiosemicarbazones bearing pyrazole nucleus. The study is described in the following
parts.
PART-I :  STUDIES ON PYRAZOLYLPYRAZOLINES
Pyrazoline derivatives are endowed with different therapeutic activities such as
antibacterial, analgesic, antitubercular, antiinflammatory, anticancer etc. These valid
observation led us to synthesise some novel pyrazoline derivatives bearing 1-Phenyl-3-
o-ethoxyphenyl-4-formyl pyrazole moiety, which have been described as under.
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-(1',N-phenyl-3'-
o-ethoxyphenyl-pyrazol-4'-yl)-2-propen-1-ones
2The chalcone derivatives of type (I) have been prepared by the condensation of
1-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole with different aryl ketones in the
presence of 40% NaOH.
SECTION -II : Synthesis and biological evaluation of 1,N-Acetyl-3-aryl-5-
(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
The pyrazoline derivatives of type (II) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid.
SECTION -III : Synthesis and biological evaluation of 1,N-Phenyl-3-aryl-5-
     (1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
N
N
OCH3
R
O
                                                          Type (I)             R = Aryl
N
N
N NH3COC
R
OCH3
                                                          Type (II)               R = Aryl
3The pyrazolines of type (III) have been prepared by the reaction of compounds
of type (I) with phenyl hydrazine in presence of basic catalyst like piperidine.
PART - II : STUDIES ON CYANOPYRIDONES
Cyanopyridone ring systems have a prominent feature in medicinal chemistry and
possess biological activities such as analgesic, insecticidal, antibacterial, antidiabetic,
anticonvulsant etc. In view of these facts, it was contemplated to synthesize
cyanopyridone derivatives which have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-Cyano-4-(1',N-phenyl-
 3'-o-ethoxyphenyl-pyrazol-4'-yl)-6-aryl-1,2-dihydro-2-pyridones.
The cyanopyridones of type (IV) have been prepared by the condensation of
chalcones of type (I) with ethylcyanoacetate and ammonium acetate.
N
N
N
N
R
OCH3
                                                          Type (III)              R = Aryl
N
N
OCH3
NH
O
R
N
                                                          Type (IV)               R = Aryl
4PART-III :  STUDIES ON ISOXAZOLES
Isoxazole plays a vital role owing to their wide range of biological activities like
antifungal, antibacterial, sedative, hypnotics, antiallergic etc. In light of these findings,
synthesis of some new isoxazole derivatives incorporating the pyrazole nucleus has been
under taken in order to assess their pharmacological profile which have been described
as under.
SECTION - I : Synthesis and biological evaluation of 3-Aryl-5-(1',N-phenyl-3'-
o-ethoxyphenyl-pyrazol-4'-yl)-isoxazoles
The isoxazole derivatives of type (V) have been prepared by the reaction of
chalcones of type (I) with anhydrous sodium acetate and hydroxylamine hydrochloride
in glacial acetic acid.
PART - IV : STUDIES ON THIOSEMICARBAZONES
These derivatives have been extensively studies because of their broad spectrum
of biological activities such as antitubercular, antimicrobial, anticancer, insecticidal,
antidiabetic etc. With a view to getting better therapeutic agents and a study their
pharmacological profile, the synthesis of some new thiosemicarbazone derivatives have
been under taken as under.
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-(1',N-phenyl-3'-
o-ethoxyphenyl-pyrazol-4'-yl)-2-propene-1-thiosemicarbazones
N
N
O N
R
OCH3
                                                          Type (V)            R = Aryl
5The thiosemicarbazones of type (VI) have been prepared by the condensation of
chalcones of type (I) with thiosemicarbazide.
PART - V : STUDIES ON IMIDAZOLINONES
Imidazolinone derivatives have been found to be potent drug in pharmaceutical
and possess a wide range of biological activities such as anticonvulsant,
antiinflammatory, hypnotic, sedative, antihistamine and antithyroid. In order to develop
medicinally important compounds, we have synthesised some new imidazolinones
shown as under.
SECTION - I : Synthesis and biological evaluation of 1,N-Aryl-2-phenyl-4-(1’,N-
phenyl-3’-o-ethoxyphenyl-4’-pyrazolylmethino)- imidazolin-5-ones
N
N
N
OCH3
R
NH S
NH2
                                                          Type (VI)                   R = Aryl
N
N
OCH3
N
N
R
O
                                                          Type (VII)               R = Aryl
6The imidazolinone derivatives of type (VII) have been prepared by the reaction
of azalactone with different aryl amine in pyridine.
PART - VI : STUDIES ON α-ARYLAMINONITRILES
Recently substituted nitrile derivatives have drawn considerable attention due to
their good pharmacological activities like cardiovascular, sedative, antifungal and
antibacterial. By considering these valid observations, we have synthesised some new
nitriles which have been described as under.
SECTION - I : Synthesis and biological evaluation of α-Arylamino-(1’,N- phenyl-
3’-o-ethoxyphenyl-pyrazol-4’-yl)-acetonitriles
The nitriles of type (VIII) have been prepared by the condensation of 1,N-
phenyl-3-o-ethoxyphenyl-4-formyl pyrazole with different aromatic amines in presence
of sodium cyanide and glacial acetic acid at 0-5 oC.
[B] STUDIES ON TRIAZOLES
Compounds bearing 1,2,4-triazole nucleus are endowed with a variety of
biological activities such as amoebicidal, hypnotic, plantgrowth regulator, fungicidal
anti-inflammatory, CNS depressant, antitumor, anticonvulsant etc.
Considering the increasing importance of triazole nucleus, we have undertaken
synthesis of some novel dihydrothiadiazoles, thiadiazepines and thiadiazine bearing triazole
nucleus, which have been described as under.
                                                         Type (VIII)              R = Aryl
N
N
OCH3
NH
R
N
7PART - I : STUDIES ON 1,3,4-THIADIAZEPINE
Thiadiazepine derivatives have been reported to possess various biological
activities like antifungal, antibacterial, antiamoebic, anti-HIV and anticancer. To approach
these goal ,synthesis of some novel thiadiazipines have been undertaken as under.
SECTION - I : Synthesis and biological evaluation of 3-(p-hydroxyphenyl)-[1,2,4]-
triazolo[3,4-b]substituted quinolino[3’,2’-f]-1,3,4-thiadiazepines
Thiadiazepine derivative of type (IX) have been prepared by the condensation of
3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole with substituted 2-chloro-3-
formyl-quinolines.
PART - II : STUDIES ON THIADIAZINES
Thiadiazine are endowed with different therapeutic properties such as  analgesic,
antibacterial, antifungal, anthelmintic, antiinflammatory, cardiovascular etc. Considering
these findings, we thought it worthwhile to synthesise some new 1,3,4-thiadiazine
derivatives in order to achieve potent agents, which have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-(p-hydroxyphenyl)-6-aryl-
 7H-[1,2,4]-triazolo[3,4-b]-1,3,4-thiadiazines
                                                          Type (IX)               R = Aryl
N
N N
N
N
S
OH R
                                                          Type (X)              R = Aryl
N N
N
N
S
OH
R
8The thiadiazine derivatives of type (X) have been prepared by the
condensation of  3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-trizole with
different phenacylbromide.
[C] STUDIES ON MICROWAVE INDUCED SYNTHESIS OF 5,6-
DIHYDRO-1,3,4-THIADIAZOLOTRIAZOLES
In the recent years, MORE (Microwave Induced Organic Reaction Enhancement)
technique has become very popular due to substantial reduction in reaction time,
operational time, operational simplicity and formation of clear reaction products. Keeping
this in view, we investigated the synthesis of the dihydrothiadiazoles using microwave
irradiation and also by conventional method.
PART - I : STUDIES ON 5,6-DIHYDRO-1,3,4-THIADIAZOLO-TRIAZOLES
BY CONVENTIONAL AND MICROWAVE INDUCED SYNTHESIS
Dihydrothiadiazoles possess remarkable pharmacological importance and
biological activities such as antifungal, antibacterial, pesticidal, antithyroid etc. Prompted
by above facts, some new dihydrothiadiazoles have been prepared which have been
described as under.
SECTION – I : Synthesis and biological evaluation of 3-(p-hydroxyphenyl)-
5,6-dihydro-6-aryl-[1,2,4]-triazolo[3,4-b] [1,3,4]- thiadiazoles
by conventional method
The compounds of type (XI) have been prepared by the condensation of
3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole with different aromatic
aldehydes in the presence  of p-toluenesulphonic acid.
                                                          Type (XI)           R = Aryl
N N
N
N
H
S
OH
R
9SECTION - II : Synthesis and biological evaluation of 3-(p-hydroxyphenyl)-
5,6-dihydro-6-aryl-[1,2,4]-triazolo[3,4-b] [1,3,4]- thiadiazoles
by microwave method.
The compounds of type (XII) have been prepared by the condensation of
3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazol with different aromatic
aldehydes in the presence of p-toluenesulphonic acid under microwave irradiation in
few minutes. The advantages of microwave synthesis has been reported.
CHARACTERISATION
The constitution of newly synthesised products have been supported by using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been checked
by thin layer chromatography.
In vitro study on multiple biological activities
   (i) All the compounds have been evaluated for their antibacterial activity towards
Gram positive  and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg. The biological activity
of  the synthesised compounds have been  compared with standard drugs.
   (ii) Selected compounds have been evaluated for their in vitro biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 µg/ml using Rifampin as a standard drug,which
have been tested by Tuberculosis Antimicrobial Acquisition Coordinating
Facility (TAACF), Alabama,U.S.A.
                                                          Type (XII)              R = Aryl
N N
N
N
H
S
OH
R

10Searching New...
INTRODUCTION
The primary objective of medicinal chemistry is the design and discovery
of new compounds that are suitable for use as drugs. This process requires a team
effort. It not only involves chemists but also workers from a wide range of
disciplines such as biology, biochemistry, pharmacology, computing and medicine,
amongst others.
Chemistry related with pharmaceutically important compounds is mainly
divided in two parts. The first, chemotherapy, concerns the treatment of infections,
parasites or maligant diseases by chemical agents, usually substances that shows
selective toxicity towards the pathogen. The other division relates to diseases of
bodily disfunction and the agents employed are mainly compounds that effect the
functioning of enzymes, the transmission of nerve impulses or the action of
hormones on receptors.
Research in the field of pharmaceutical has its most important task in the
development of new better drugs and their successful introduction into clinical
practice. Central to these efforts, accordingly stand the search for pharmaceutical
substances and preparation which are new and original. In addition to these
objectives, we may search for newer drugs which exhibit some clear advantages
over a drug already known. Such advantages may be qualitative or quantitative
improvement in activity, the absence of undesirable side effects, lower toxicity,
improved stability or decreased cost.
Heterocyclic compounds show vital role in the field of pharmaceuticals.
Heterocyclic compounds are used because they have a specific clinical reactivity,
for example epoxides, aziridines and β-lactams. The introduction of heterocyclic
group into drugs may affect their physical properties, for example the dissociation
constants of sulpha drugs or modify their patterns of absorption, metabolism or
toxicity.
11Searching New...
The word ‘drug’ is derived from the french word ‘drogue’ which means a
dry herb. According to “WHO” a drug may be defined as “any substance or product
which is used or intended to be used for modifying or exploring physiological
system or pathological status for the benefit of recipient”.
Drugs action is believed to be due to the interaction of the drug with
enzymes, receptors and other molecules found in the biological system. The binding
of a drug to the active or other sites of an enzyme usually has the effect of preventing
the normal operation of that enzyme. The drug’s therapeutic effect will depend on
the stability of the drug-enzyme complex as well as the fraction of active and
allosteric sites occupied by the drug. The stronger the binding of the drug to the
enzyme and greater the number of sites occupied, the more effective the drug is
likely to be in inhibiting the action of the enzyme.
The degree of drug activity is directly related to the concentration of the
drug in the aqueous medium in contact with the active or receptor site. The factors
affecting this concentration in a biological system can be classified in to two phase.
(I) The pharmacokinetic phase
It is concerned with the study of the parameters that control the journey of
the drug from its point of administration to its point of action. It includes the
absorption, distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase
It is concerned with the result of the interaction of drug and body at the
receptor site, that is, what the drug does to the body. This includes physiological
and biochemical effects of drugs and their mechanism of action at macromolecular
/subcellular organ systems.
12Searching New...
The role of the medicinal chemist is to design a drug structure that has the
maximum beneficial effects with a minimum of side effects. This design has to
take into account the stereoelectronic characteristics of the target active or receptor
site and also such factors as the drug’s stability in situ, its polarity and its
relative solubilities in aqueous media and lipids. The stereochemistry of the drug
is particularly important because stereoisomers often have different biological
effects that range from inactive to highly toxic.
In the nineteenth century, chemistry was developed as a science, both in
terms of experimental procedures and scientific theory. Scientist isolated and
purified single compounds from natural extracts. Method of organic synthesis were
developed that helped chemists altering structures in a predictable way. The chemists
started separating out the various components of ancient positions to discover
whether a single compound was responsible for the medicinal effect known as the
active principle.
A large number of important drugs have been introduced during the period
of 1940 to 1960. This perod is knowns as ‘Golden Period’ of new drug discovery.
Thus starting from 1933-the first antibacterial drug prontosil leading to various
sulpha drugs; 1940-penicillin, antibiotics; 1945-chloroquine, antimalarial; 1950-
methyldopa, antihypertensive; 1957-chlorthiazide, diuretic; 1958-adrenergic beta
blockers coronary vasodilatory; 1960-semi synthetic penicillin, antibacterial; 1965-
trimethoprim, antimicrobial; 1967-disodium chromoglycoate, antiallergic; 1972-
cimetidine, H2-antagonist; 1975-verapamil, calcium antagonist; 1981-captopril,
antihypertensive. There are some specific examples representing new therapeutics.
AIMS AND OBJECTIVES
In the pharmaceutical field, there have always been and will continue to be
a need for new and novel chemical inhibitors of biological function. Our efforts
are focused on the introduction of chemical diversity in the molecular frame work
in order to synthesizing pharmacologically interesting compounds of widely
different composition.
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During the course of our research work, looking to the application of
heterocyclic compounds, several entities have been designed, generated and
characterized using spectral studies. The details are as under.
♦ To generate several derivatives like pyrazolines, cyanopyridones, isoxazoles,
imidazolinones, acetonitriles and thiosemicarbazones bearing pyrazole
nucleus.
♦ To generate derivatives like 1,3,4-thiadiazepines and 1,3,4-thiadiazines
bearing 1,2,4-triazole nucleus.
♦ To synthesise biologically active 2,3-dihydro-1,3,4-thiadiazolotriazoles
bearing 1,2,4-triazole nucleus using microwave induced synthesis method.
♦ To check purity of all the compounds using thin layer chromatography.
♦ To characterise these products for stucture elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
♦ To evaluate new products for better drug potential against different strains
of bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37Rv.
    [A]
STUDIES ON
PYRAZOLES
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INTRODUCTION
Pyrazole refers both to the class of simple aromatic ring compounds of the
heterocyclic series characterised by a five membered ring structure composed of
three carbon atoms and two nitrogen atoms in adjacent positions (I). Being so
composed and having phamacological effects on humans, they are not known to
occur in nature.
Pyrazole exhibits characteristic reactions of pyrrole and pyridine because of
containing pyrrole type and pyridine type nitrogen atoms at the position-1 and
position-2. Pyridine type nitrogen is susceptible to electrophilic attack but it is
less nucleophilic than the pyridine nitrogen atom. The hydrogen atom attached to
the nitrogen atom in pyrazole is more acidic than the pyrrolic N-H in pyrrole and
can be easily removed by nucleophiles.
Pyrazole exists in two tautomeric forms.
N
H
N
(I)
N
H
N
N
NH
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Knorr1,2 first synthesised a compound containing this system in 1883 by a
reaction of ethylaceto acetate with phenyl hydrazine which yielded 1-phenyl-3-
methyl-5-pyrazolone (II). Knorr3 introduced the name pyrazole for these compounds
to designate that the nucleus was derived from pyrrole by replacement of carbon by
nitrogen. Pyrazole ring is incorporated in to many of the pharmaceuticals,
agrochemicals and dyestuffs.
SYNTHETIC ASPECTS
Various methods for the preparation of pyrazoles have been cited in literature.
1. L. Knorr4 has synthesised two structrually isomeric pyrazoles by the
condensation of substituted hydrazines with 1,3-dicarbonyl compounds.
2. M. J.  Kurth5 and et.  al .  suggested a novel route for synthesis of fully
substituted 1H-pyrazoles.
N
N
C6H5
O
CH3
(II)
O
R
O
R2
R1 + NH2 NH
Ar N
N
R1
R2
Ar
R
+
N
N
R2 R1
Ar
R
+ 2H2O
(III)
N N
N N
C6H5H5C6 + S
OPh
KOH-MeOH
N
N
OH C6H5
CH2 C6H5
MeO
Ph
(IV)
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3. R. C. Boruah6 and et. al. suggested one pot synthesis of pyrazoles from
β-formyl enamides.
4. By the reaction of 1,3-dinitroalkanes with hydrazines7.
5. H. V. Pechmann8 has synthesised pyrazoles by the reaction of acetylene
and diazomethane.
THERAPEUTIC IMPORTANCE
Pyrazole derivatives have been reported to be associated with diverse
biological activities.  Drug molecules having pyrazole nulceus with good
pharmacological activities are listed below.
NHAcOHC
R1R2
NH2OH.HCl
N
N
R1
Ac
R2
KH2PO4
R1
NO2
R2
+
NO2
R3
NO2NO2
R3
R2
R1
NH2 NH
R4
NN
R4
R3
R2
R1
CH CH + CH2 N N
N
NH
+ -
(V)
(VI)
(VII)
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N
N
CH3
H2NO2S
CF3
Celecoxib
(Antiinflammatory)
N
N
O
CH3
CH3
N
CH2SO3Na
CH3
Novalgin
(Antipyretic, Analgesic)
N
N
N
N
Cl Cl
F3C
N
NH
SCH2
F
Pyrafluprole
(Insecticide)
N
NO
OH3C(H2C)3
OH
Oxyphenbutazone
(Antiarthritic)
N N
N
OH
O
CH3
Cl
H3CO
Tepoxalin
(Antiinflammatory)
N
N
N
N CH3
O
CH3
N
Zaleplon
(Sedative, Hypnotic)
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Pyrazole derivatives exhibit broad spectrum of therapeutic activity. Several
biological activities associated with pyrazole derivatives have been described as
under.
(a) Anticancer9
(b) Antitumor10
(c) Antiulcer11
(d) Antimicrobial12
(e) Antiparasitic13
(f) CNS depressant14
(g) Herbicidal15
(h) Immunosuppresants16
(i) Lipoxygenase inhibitor17
(j) Neurotonsin receptor18
Menozzi G. and co-workers19 have synthesised a series of N-substituted
4-carboxy-1-phenyl-lH-pyrazole-5-propanamides. In which some compounds
showed a platelet antiaggregating activity in vitro superior or comparable to that of
acetyl-salicylic acid, as well as moderate antiinflammatory, analgesic and antipyretic
activities in rats or mice.
Naito H. et. al.20 have synthesised pyrimidinyl pyrazole derivatives which
exhibited a potent cytotoxic activity against some tumor cell lines including
multidrug resistant cell lines due to the overexpression of P-glycoprotein. Several
new 1-methyl-5-[substituted-4-oxo-1,2,3-benzotriazin-3-yl]-1H-pyrazole-4-
acetic acids and their ethyl ester derivatives were prepared and tested for analgesic
and antiinflammatory activities, acute toxicity, ulcerogenic effect, and as in vitro
Chlorprazophos
(Insecticide)
N
N
N
CH3
Cl
O
P
O
O
O
CH3
CH3
H
CH3
H
CH3
H
OH
H
CH3
N
N
H
Stanozolol
(Insecticide)
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inhibitors of 3α-hydroxysteroid dehydrogenase (3α-HSD) by Giuseppe Daidone21.
Ejima Akio et. al.22 have synthesized pyrazole derivatives as antitumor agents (VIII).
Stevan W. Djuric and co-workers23 have identified a series of bis
(trifluoromethyl)pyrazoles (BTPs) as a novel inhibitor of cytokine production and
even inhibit IL-2 production with a 10-fold enhancement over cyclosporine in an
ex vivo assay.
 Nagaaki Sato et. al.24 have prepared arylpyrazole derivatives and evaluated
as neuropeptide Y5 receptor antagonist. One of the compound with chiral 2,3-
dihydro-1H-cyclopenta[a]naphthalene moiety, showed good binding affinity and
antagonistic activity for the Y5 receptor. Virinder S. Parmar et. al.25 have synthesised
pyrazole derivatives (IX) and studied their antiinvasive activity.
Carbau Romuald and co-workers26 have reported pyrazole derivatives useful
as reverse transcriptase inhibitors for the treatment of HIV infection. J. Scott Sawyer
et. al.27 have developed an interesting series of pyrazole based inhibitors of the
Transforming Growth Factor-β Type I Receptor Kinase Domain. David L. S. et. al.28
have reported pyrazoles as activators of the nitrile oxide receptor and soluble
guanglate cyclase agent.
N
N
N
CH3
Cl
N
N
Cl
F
(VIII)
N N
H
Cl
H
N
F
F
(IX)
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Akihiko Tanitame and co-workers29 have synthesized new pyrazole
derivatives and found that 5-[(E)-2-(5-chloroindol-3-yl)vinyl]pyrazole possesses
potent antibacterial activity and selective inhibitory activity against bacterial
topoisomerases. Many of the synthesized pyrazole derivatives were potent against
clinically isolated quinolone or coumarin-resistant Gram-positive strains.
T. Van Herk et. al.30 have demonstrated pyrazoles as nicotinic acid receptor
(X). Atkinson R. N. et. al.31 have synthesized pyrazoles as sodium channel Blocker
(XI). Pyrazole derivatives as TGF-13 inhibitors have been suggested by Gellibert
Francoise et. al.32.
A series of 3-(4-phenoxyphenyl)-1H-pyrazoles(XII) were synthesized and
characterized as potent state-dependent sodium channel blockers by Ji Yang and
co-workers33.
Zainaba D. et. al.34 have investigated 1-phenyl-3-toluyl-4-[ortho-1’-(N-
ethyl-2’-methylpropylamine)]phenylpyrazole as antifungal agent and showed that
mycelial growth and conidial germination of fungi were blocked by the compound.
Adnan and Tarek35 have synthesised pyrazole derivatives (XIII) and tested for their
antiinflammatory, cyclooxygenase-2-inhibitory and antimicrobial activities.
N
H
N
R2
R1
COOH
N
N
Cl
F3C
NH
O
N
(X) (XI)
O
N
N
O
NH2
R
(XII)
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A novel series of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole
derivatives have been synthesised by Franco Chimenti et. al.36 and investigated
for the ability to inhibit selectively the activity of the A and B isoforms of
monoamine oxidase (MAO).
Craig W. Lindsley et. al.37 have investigated positive allosteric Modulators
for the Metabotropic Glutamate Receptor from a series of N-(1,3-diphenyl-1H-
pyrazol-5-yl)benzamides that potentiate receptor function in vivo. Several 5-substituted
pyrazole derivatives have been prepared as potent CB1 antagonists by Raj K.
Razdan38. These compounds have good binding affinities and also they may prove
to be clinically useful for the treatment of obesity. Adrian l. Gill and Martyn
Frederickson and co-workers39 have identified pyrazole as a novel p38α MAP
kinase inhibitors (XIV).
N
N
N NR
S
Br
(XIII)
N
O
NH NH
O NN
Cl
CH3
CH3
CH3
(XIV)
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Recently, Bantwal Holla and co-workers40 have synthesised pyrazole
derivatives as potential antimicrobial agents. Antimalarial activity of 4-(5-trifluoro
methyl-1H-pyrazol-1-yl)-chloroquine analogues has been evaluated in vitro against
a chloroquine resistant Plasmodium falciparum clone by Antoniana U. Krettli et.
al.41. Pyrazole derivatives (XV) with nanomolar activity in the biochemical assay
and able to efficiently inhibit CDK2-mediated tumor cell proliferation have been
obtained by Paolo Pevarello et. al.42.
Structure–activity relationship (SAR) studies of the novel 2-[3-di and
trifluoromethyl-5-alkylamino pyrazo-1-yl]-5-methanesulfonyl (SO2Me)/sulfamoyl
(SO2NH2)-pyridine derivatives for canine COX enzymes are described by Subas
M. Sakya et. al.43. The studies led to the identification of (XVI) as lead with potent
in vitro activity, selectivity, and in vivo activity in dogs and cats.
Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activity, it appeared
of interest to synthesize some chalcones, pyrazolines, cyanopyridones, isoxazoles,
thiosemicarbazones, imidazolinones and α-arylaminonitriles bearing pyrazole
moiety in order to achieving compounds having better therapeutic importance. These
studies are described in following parts.
N
H
N N
NH
R1
O
O
R
(XV)
N
N
N CF2H
CN
H3CO2S
N
O
CH3
CH3
(XVI)
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INTRODUCTION
Amongst nitrogen containing five membered heterocycles, pyrazolines have
proved to be the most useful frame work for biological activities. Pyrazolines have
attracted attention of medicinal chemist for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. In 1967 Jacobe,
reviewed the chemistry of pyrazolines, which have been studied extensively for
their biodynamic behavior44 and industrial applications.45
The pharmaceutical importance of these compounds lies in the fact that they
can be effectively utilized as antibacterial, antifungal, antiviral, antiparasitic,
antitubercular and insecticidal agents.
As evident from the literature, in recent years a significant portion of research
work in heterocyclic chemistry has been devoted to pyrazolines containing different
aryl groups as substituents.
SYNTHETIC ASPECTS
Different methods for the preparation of 2-pyrazoline derivatives documented
in literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
hydrazine hydrate46.
N
H
N
R O
R1
+ NH2.NH2.H2O
N
H
NR
R1
R, R1 = Aryl
25Pyrazoline...
2. 2-Pyrazoline can be prepared by the condensation of α, β-unsaturated ketone
and thiosemicarbazide in the presence of basic alumina and K2CO347.
3. 2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to
substituted chalcone.48
4. Dipolar cycloaddition of nitrileimines of dimethyl fumarate, fumaronitrile
and the N-aryl maleimides yielded the corresponding pyrazolines.49
5. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine
hydrate and phenyl hydrazine to give pyrazolines.50
6. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazine.51
Furthermore, B. Gyassi et. al.52 have investigated the one pot synthesis of
some pyrazolines in dry media under microwave irradiation. S. Paul et. al.53 and
Dandia Anshu et. al.54 have also described the microwave assisted synthesis of
2-pyrazolines.
MECHANISM
The following mechanism seems to be operable for formation of pyrazoline
by the condensation of chalcones with hydrazine hydrate.55
RO
R1
+
N
NR
R1
S NH2
NH2
NH NH2
S
BASIC ALUMINA
K2CO3
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Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system forms species (II), in which the negative charge is mainly accommodated by the
electronegative oxygen atom.
Proton transfer from the nitrogen to negative oxygen produces an
intermediate enol which simultaneously ketonises to ketoamine (III). Another
intramolecular nucleophillic attack by the primary amino group of ketoamine on
its carbonyl carbon followed by proton transfer from nitrogen to oxygen leads
to carbonyl amine (IV). The later with a hydroxy group and amino group on the
same carbon loses water molecule to yield the pyrazolines.
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazolines are better
therapeutic agents. Some of the activities are mentioned below.
(a) Antiallergic56
(b) Anticonvulsant57,58
(c) Antiimplantation59
(d) Antiinflammatory60
(e) Antitumor61
(f) Antineoplastic62
(g) Antimicrobial63
(h) Analgesic64,65
R
CH
CH
C
R1
O
CH
CHR
NH
NH2R2
C
O
R1
..
_
+
..
proton transfer
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CH
R
N
NH2R2
CH2
C
O
R1
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CH2
C
N
H
CH
N
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(i) Bactericidal66,67
(j) Cardiovascular68
(k) Diuretic69
(l) Fungicidal70
(m) Herbicidal71
(n) Hypoglycemic72
(o) Insecticidal73
(p) Tranquilizer74
Tuntawy Atif and coworkers75 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agent. Kawazura H. and co-workers76
have suggested that (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline possesses potent
cerebroprotective effects in the rat focal cerebral ischemia model. A series of
3-styryl-1,5-diphenyl and 5-styryl-1,3-diphenyl-2-pyrazolines of different
substitutions has been synthesised as antibacterial and antimycotic agents by
Nauduri D. and Reddy G. B. S77.
Almstead J. et. al.78 have prepared pyrazolines for use in increasing
erythropoietin and vascularization of tissue. Guniz Kucukguzel et. al.79 have
synthesized pyrazoline derivatives as a antimicrobial and anticonvulsant agents.
One of the compound showed 40% protection against pentylenetetrazole induced
seizures in albino swiss mice. Shalabh Sharma  et. al.80 have synthesized pyrazolines
and tested their antiinflammatory activity (I). Ashok Kumar et. al.81 have synthesized
pyrazolines as anticonvulsant agents (II).
NH
N N
S
NH
N
N
COCH3
R
N
H
NH
N N
OCH3
OS
O
COCH3
(I) (II)
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Maurer Fritz et. al.82 have synthesized pyrazolyl pyrazolines. In spodoptera
frugiperda pesticide studies with Brassica oleracea, at 500 ppm some of compounds
exhibited 100% mortality after seven days and some of compounds were claimed
to be useful as pesticidal coating material agents. Moritaz Z. and Hadol83
investigated a semi imperial molecular orbital study on the reaction of amino
pyrazolinyl azo dye with singlet molecular oxygen. Malhotra V. et. al.84 have
synthesized new pyrazolines as a cardiovascular agent (III).
Moreover, Ahn J. H. et. al.85 have described the synthesis and DP-IV
inhibition of cyano-pyrazoline derivatives as potent antidiabetic agents (IV). Jeong
T. S. et. al.86 have synthesized some novel 3,5-diaryl pyrazolines as human acyl-
CoA:cholesterol acyl transferase inhibitors. Berghot M. A. et. al.87 have prepared
convergent synthesis and antibacterial activity of pyrazole and pyrazoline derivatives
of diazepam.
Matysiak J. et. al.88 have sythesised some novel pyrazoline derivatives which
exhibited comparable or higher activity than itraconazole and fluconazole tested
under the same experimental condition. Tabarelli Z. et. al.89 have prepared some
pyrazole derivative showing activity of antinociceptive effect of novel pyrazolines
in mice. Tae-Sook Jeong et. al.90 have reported pyrazole as low-density lipoprotein
(LDL) oxidation inhibitor (V). One of the compound was 6-fold more potent than
probucol in the TBARS assay.
N
N S
NH R2
R1
Ph
   (III)       R1, R2 = Aryl
N NH
NH
N
O
N
NC
CN
 (IV)
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Mohammad Abid and Amir Azam91 have synthesised 1-N-substituted
cyclised pyrazoline analogues of thiosemicarbazones and reported their antiamoebic
activities (VI). B. Bizzarri et. al.92 have reported in vitro selective anti-helicobacter
pylori activity of pyrazoline derivatives.
CONTRIBUTION FROM OUR LABORATORY
S. D. Sorthiya et. al.93 have synthesised and tested the antimicrobial activity
of p-(2',5'-Dibromobenzenesulphonamido)-phenyl-5-aryl-1H/acetyl/phenyl-2-
pyrazolines. Parekh et. al.94 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-
methyl-4-one-3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial
activity.
Parikh et. al.95 have synthesised some antimicrobial pyrazolines. Tejas
Upadhyay et. al.96 and Sohit Rajvaidya et. al.97 have prepared pyrazolines as
antimicrobial agent. A. V. Dobaria and co-workers98 has discovered pyrazolines
bearing chloroquinoline nucleus as antimicrobial agents (IX).
N N
H
t-Bu
OH
t-Bu
R1 R2
OH
R3
 (V)   R1,R2,R3 = Alkyl
N
N
Cl
N
S
CH2-CH2-CH3
CH2-CH2-CH3
 (VI)
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Recently, Abd El-Galil E. Amr et. al.99 have synthesised some new
3-substi tuted androstano[17,16-c ]-5’-aryl-pyrazolines and reported their
antiandrogenic activity. Amir Azam and co-workers100 have synthesised some
pyrazoline derivatives and tested their antiamoebic activity. Some of the compounds
were found with IC50 lower than that of the standard drug metronidazole and thus
are better inhibitor of growth of E. histolytica. Y. Rajendra Prasad et. al.101 have
synthesised some 1,3,5-triphenyl-2-pyrazolines and 3-(2’’-hydroxy naphthalen-1”-yl)-
1,5-diphenyl-2-pyrazolines and reported as antidepressant (VII) & (VIII).
 (VII)  (VIII)
N N
R1
R2
R3
R4
N N
R2
R3
OH
R1
R4
 R1, R2, R3, R4 = Alkyl
NCH3 Cl
N
H
N
R
R = Aryl(IX)
Thus interesting biological activities of a novel heterocycle like pyrazoline
have stimulated considerable research work in recent years leading to the synthetic
utility of the derivatives of this ring system. In our search for new potential
antimicrobial compounds, the reaction series of chalcones with hydrazine hydrate/
phenylhydrazine under different conditions has been investigated and the
pharmacological profile of the compounds have been studied and described as under.
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SECTION-I   : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1-ARYL-3- (1 ' ,N-PHENYL-3' -O -ETHOXYPHENYL-
PYRAZOL-4'-YL)-2-PROPEN-1-ONES
SECTION-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1 , N - A C E T Y L - 3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - O -
ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1 , N - P H E N Y L - 3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - O -
ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1' ,N-
PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPEN-1-ONES
With the biodynamic activities of chalcones and as it is a good synthon for
various heterocyclic rings, the interest has been focussed on the synthesis of newer
chalcones. With a view to obtaining compounds having better therapeutic activity,
we have synthesized 1-aryl-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-2-
propen-1-ones by the condensation of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl
pyrazole with various aromatic ketones in the presence of 40 % NaOH.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. Purity of all compounds have been
checked by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
R
O
Type (I)            R = Aryl
33Pyrazoline...
NH
NH2
+
Abs. C2H5OH
gl. CH3COOH
Formylation by
Vilsmeier-Haack
CH3
O
O
CH3
NH
N
CH3
O
CH3
N
N
OCH3
CHO
R CH3
O
40 % NaOH
N
N
OCH3
O
R
REACTION SCHEME
Type - (I) R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1' ,N-
PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPEN-1-ONES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
A mixture of phenylhydrazine (1.08 g, 0.01 M) and o-ethoxyacetophenone
(1.64 g, 0.01 M) in absolute ethanol was refluxed in water bath for 2 hrs. in the
presence of 1ml of glacial acetic acid. Product obtained after cooling was crystallised
from absolute ethanol. Yield 92%, m.p. 42oC (C16H18N2O; Required : C, 75.56;
H, 7.13, N, 11.01; Found : C, 75.51; H, 7.09; N,10.95%).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
o-Ethoxyphenylhydrazone(2.54 g, 0.01 M) was added into a Vilsmeier-Haack
reagent (prepared by dropwise addition of 3 ml POCl3 in ice cooled 25 ml DMF)
and refluxed for 6 hrs. The reaction mixture was poured on to crushed ice followed
by neutralization using sodium bicarbonate. Crude product was isolated and
crystallised from methanol. Yield 87%, m.p. 124oC (C18H16N2O2; Required : C,
73.95; H, 5.52; N, 9.58;  Found : C, 73.89; H, 5.48; N, 9.52%).
(C) Synthesis of 1-(p-bromophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
To a solution of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole (2.92 g,
0.01 M), p-bromoacetophenone (1.99 g, 0.01 M) in ethanol (25 ml) and 40% NaOH
was added till the solution becomes basic. The reaction mixture was stirred for 24
hrs. The contents were poured on to crushed ice. Upon neutralization, the solid
was  separa ted  and crys ta l l i sed  f rom e thanol .  Yie ld  65%,  m.p .160oC
(C26H21BrN2O2; Required : C, 65.97; H, 4.47; N, 5.92;  Found : C, 65.91; H,
4.41; N, 5.87%).
TLC solvent system : Acetone : Benzene (2 : 8).
Similarly other 1-aryl-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-2-
propen-1-ones have been prepared. The physical data are recorded in Table No. 1.
35Pyrazoline...
(D) Antimicrobial activity of 1-Aryl-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-ones
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method
which has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically with
0.5 ml of 24 hrs. old subcultures of B. coccus, S. aureus, E.aerogenes, P. aeruginosa
in separate conical flasks at 40-50oC and mixed well by gentle shaking. About
25ml content of the flask were poured and evenly spreaded in a petridish (13cm in
diameter) and allowed to set for 2 hrs. The cups (10 mm in diameter) were formed
by the help of borer in agar medium and filled with 0.04ml (40µg) solution of
sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 ml of DMF in a similar manner and the zones of inhibition
of the bacterial growth were measured in millimeter and are recorded in Graphical
Chart No.1.
The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics l ike Amoxicil l in,  Benzoyl penicil l in,
Ciprofloxacin and Erythromycin.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud’s agar slants. Sterilized Sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a
separate flask. About 25 ml of the inoculated medium was evenly spreaded in a
petridish and allowed to set for two hrs. The cups (10 mm in diameter) were punched
and filled with 0.04 ml (40 µg) solution of sample in DMF. The plates were incubated
at 30oC for 48 hrs. After the completion of incubation period, the zones of inhibition
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of growth in the form of  diameter in mm was measured. Along the test solution in
each petridish one cup was filled with solvent which acts as control. The zones of
inhibition were compared with standard antifungal agent Greseofulvin. The zones
of inhibition are recorded in Graphical Chart No. 1.
(b) Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordination Facility (TAACF),
U.S.A. Primary screening of the compounds for the antitubercular activity have
been conducted at 6.25 µg/ml towards Mycobacterium tuberculosis H37Rv in
BACTEC 12B using the BACTEC 460 radiometric system. The compounds
demonstrating atleast>90% inhibition in the primary screening has been tested at
lower concentration towards Mycobacterium tuberculosis H37Rv to determine the
actual minimum inhibitory concentration (MIC) in the BACTEC-460.
The antitubercular activity data have been compared with standard drug
Rifampin at 0.25 µg/ml concentration and it showed 98% inhibition.
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate102
Gram positive bacteria : Bacillus coccus
Staphylococcus aureus
Gram negative bacteria : Enterobacter aerogenes
Pseudomonas aeruginosa
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzoyl penicillin,
Ciprofloxacin, Erythromycin, Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Benzoyl penicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with viz Greseofulvin. The inhibition zones were measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/ml.
Standard drug : Rifampin.
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 Observed
Alkane C-H str. (asym.) 2977 2975-2950 520
-CH3 C-H str. (sym.) 2883 2880-2860   “
C-H i.p.def. (asym.) 1459 1470-1435   “
C-H o.o.p. def. (sym.) 1362 1390-1370   “
Aromatic C-H  str. 3060 3080-3030 521
C=C str. 1592 1585-1480   “
C-H i.p. def. 1106 1125-1090   “
C-H o.o.p. def   804     835-810   “
Pyrazole C=N str. 1592 1630-1590 522
moiety                                           (overlapped)
C-N str. 1211 1230-1020   “
Ether C-O-C str. (asym.) 1211 1275-1200 520
                                          (overlapped)
C-O-C str. (sym.) 1032 1075-1020   “
Chalcone C=O str. 1659 1685-1645 523
CH=CH 3060 3050-3000   “
                                          (overlapped)
Halide C-Cl str. 753     600-800 520
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
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%T
500.0750.01000.01250.01500.01750.02000.03250.0
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1362.6
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1459.0
1503.4 1538.11592.1
1659.6
2883.4
2977.9
3060.8
3419.6
IR SPECTRAL STUDY OF 1-(p-CHLOROPHENYL)-3-(1',N-PHENYL-3'-O-
ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPEN-1-ONE
N
N
OCH3
O
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
PMR SPECTRAL STUDY OF 1-(p-BROMOPHENYL)-3-(1',N-PHENYL-3'-O-
ETHOXY PHENYL-PYRAZOL-4'-YL)-2-PROPEN-1-ONE
1. 1.23-1.27 3H triplet -OCH2CH3 JCH3=6.90
2. 4.01-4.08 2H quartet -OCH2CH3 JCH2=6.89
3. 6.99-7.02 1H doublet Ar-Hf Jfg=8.30
4. 7.04-7.09 1H triplet Ar-Hg        -
5. 7.13-7.18 1H doublet CHz (vinylic) Jzy=14.89
6. 7.25-7.33 1H multiplet Ar-Hh        -
7. 7.39-7.54 4H multiplet Ar-Hc, Ar-Hb        -
Ar-Hd, Ar-Hi        -
8. 7.55-7.58 2H doublet Ar-Hkk’ Jkj=8.39
9. 7.73-7.76 2H doublet Ar-Hae Jab=8.54
10. 7.74-7.79 1H doublet CHy (vinylic) Jyz=14.78
11. 7.76-7.79 2H doublet Ar-Hjj’ Jjk=7.95
12. 8.33 1H singlet CHx        -
N
N
OCH3
O
Br
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EXPANDED AROMATIC REGION
N
N
OCH3
O
Br
ab
c
d e x
f
g
h
i
j'j
k k'
y
z
IR SPECTRAL STUDY OF 1-ARYL-3-(1',N-PHENYL-3'-O-ETHOXYPHENYL-
PYRAZOL-4'-YL)-2-PROPEN-1-ONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R   C=O str.
      1a C6H5- 1654
1b 4-NH2-C6H4- 1653
1c 4-Cl-C6H4- 1659
1d 4-Br-C6H4- 1658
1e 4-F-C6H4- 1656
1f 2-OH-C6H4- 1660
1g 4-OH-C6H4- 1654
1h 4-OCH3-C6H4- 1656
1i 4-CH3-C6H4- 1652
1j 3-NO2-C6H4- 1654
1k 3-NO2-C6H4- 1656
1l 2-C4H3S- 1655
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051015202530
ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of chalcones (type-I) revealed that all the
compounds were able to inhibit the growth of Gram positive & Gram negative
bacterial strains.
In case of gram positive bacterial strain maximum activity was observed in
compounds bearing R = 2-hydroxyphenyl and 4-hydroxyphenyl against B.coccus.
The significant activity was displayed by compounds having R=phenyl, 4-methoxy
phenyl and 4-nitrophenyl against S.aureus.
In case of gram negative bacterial strain all the compounds were least active
against P.aeruginosa, except R= 2-hydroxyphenyl and 4-methylphenyl. The
compounds having R=4-fluorophenyl and 4-nitrophenyl have shown good activity
against E.aerogenes.
ANTIFUNGAL ACTIVITY
All the compound exhibited mild activity against fungal strain A.niger except
compounds having R= 4-fluorophenyl and 3-nitrophenyl which showed good activity
against A.niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
Pyrazolines are endowed with various biological activities. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was
considered worthwhile to synthesise some new pyrazolines bearing 1,N-phenyl-3-
o-ethoxyphenyl-4-formyl pyrazole nucleus. The preparation of 1,N-acetyl-3-aryl-
5-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-pyrazolines (II) have been under
taken by cyclocondensation of chalcones of type (I) with hydrazine hydrate in glacial
acetic acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
R
O
N
N
N NH3COC
R
OCH3
NH2NH2H2O
gl. CH3COOH
Type (II)       R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-bromophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis  of  1,N-acetyl-3-(p-bromophenyl)-5-(1' ,N-phenyl-3'-o-
ethoxyphenyl-pyrazol-4'-yl)-pyrazoline
 A mixture of 1-(p-bromophenyl)-3-(1' ,N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one (4.73 g, 0.01 M) in 25 ml absolute alcohol,  hydrazine
hydrate (1 g, 0.02 M) and glacial acetic acid (10 ml) was refluxed for 8 hrs. The
reaction mixture was poured on to crushed ice. The product was isolated and
crystallised from ethanol. Yield 46%, m.p. 89oC (C28H25BrN4O2; Required : C,
63.52; H, 4.76; N, 10.58;  Found : C, 63.46; H, 4.71; N, 10.54%).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 2.
(E) Antimicrobial  activity of  1,N-acetyl-3-aryl-5-(1' ,N-phenyl-3'-o-
ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 2.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-ACETYL-3-(p-CHLOROPHENYL)-5-(1',N-PHENYL-
3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
0.0
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 802.3
 825.5
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 Observed
Alkane C-H str. (asym.) 2925 2975-2950 520
-CH3 C-H str. (sym.) 2853 2880-2860   “
C-H i.p.def. (asym.) 1459 1470-1435   “
C-H o.o.p. def. (sym.) 1394 1390-1370   “
Aromatic C-H  str. 3057 3080-3030 521
C=C str. 1557 1585-1480   “
C-H i.p. def. 1123 1125-1090   “
C-H o.o.p. def   825     835-810   “
Pyrazole C=N str. 1597 1630-1590 522
moiety C-N str. 1123 1230-1020   “
                     (overlapped)
Ether C-O-C str. (asym.) 1245 1275-1200 520
C-O-C str. (sym.) 1039 1075-1020   “
Pyrazoline C=O str. 1663 1660-1600 524
C=N str. 1603 1630-1590   “
C-N str. 1245 1230-1020   “
Halide C-Cl str.   753     600-800 520
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
N NH3COC
OCH3
Cl
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 1,N-ACETYL-3-(p-BROMOPHENYL)-5-(1',N-PHENYL-3'-
O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.32-1.37 3H triplet -OCH2CH3 JCH3=6.8
2. 2.345 3H singlet -COCH3                   -
3. 3.07-3.13 1H double CHl Jlk=17.6
doublet Jlj=4.4
4. 3.39-3.47 1H double CHk Jkl=17.6
doublet Jkj=12
5. 3.90-4.01 2H quartet -OCH2CH3 JCH2=7.2
6. 5.75-5.79 1H double CHj Jjk=11.6
doublet Jjl=4.4
7. 6.83-6.85 1H doublet Ar-Hf Jfg=8.4
8. 6.98-7.01 1H triplet Ar-Hg        -
9. 7.22-7.31 2H multiplet Ar-Hh, Ar-Hc        -
  10. 7.38-7.45 5H multiplet Ar-Hb, Ar-Hd
Ar-Hi, Ar-Hnn’        -
  11. 7.48-7.50 2H doublet Ar-Hae Jab=8.4
  12. 7.68-7.70 2H doublet Ar-Hmm’ Jjk=7.6
  13. 7.82 1H singlet CHx        -
N
N
N NH3COC
OCH3
Br
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EXPANDED AROMATIC REGION
N
N
N NH3COC
OCH3
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Sr.
No. R    C=O str.
      2a C6H5- 1664
2b 4-NH2-C6H4- 1660
2c 4-Cl-C6H4- 1663
2d 4-Br-C6H4- 1658
2e 4-F-C6H4- 1666
2f 2-OH-C6H4- 1660
2g 4-OH-C6H4- 1664
2h 4-OCH3-C6H4- 1668
2i 4-CH3-C6H4- 1670
2j 3-NO2-C6H4- 1662
2k 3-NO2-C6H4- 1667
2l 2-C4H3S- 1665
IR SPECTRAL STUDY OF 1,N-ACETYL-3-ARYL-5-(1',N-PHENYL-3'-O-ETHOXY
PHENYL-PYRAZOL-4'-YL)PYRAZOLINES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data, it has been observed that the compounds bearing
R=phenyl, 4-tolyl have displayed significant activity against B.coccus. The
compounds bearing R=2-hydroxyphenyl, 4-methoxyphenyl have shown good activity
against S.aureus.
In case of Gram negative bacterial strains, the compounds with R=4-
fluorophenyl, 3-nitrophenyl and 4-nitrophenyl have shown considerable activity
against E.aerogenes. The maximum activity was displayed by the compounds
bearing R=2-aminophenyl and 4-methoxyphenyl against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-methoxyphenyl have displayed
highest activity against A.niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
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SECTION - III
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-ARYL-
5-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
Pyrazoline derivatives represent one of the most active class of compounds
having a wide spectrum of biological activities. Looking to the interesting properties
of pyrazolines it was considered worthwhile to synthesise a series of pyrazolines
of type-(III) for obtaining biologically potent agents which were prepared by reacting
chalcones of type (I) with phenyl hydrazine in the presence of piperidine.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
R
O
N
N
N N
R
OCH3
C6H5NHNH2
Piperidine
Type (III)       R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-ARYL-
5-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-chlorophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis  of  1,N-phenyl-3-(p -chlorophenyl)-5-(1' ,N-phenyl-3'-o -
ethoxyphenyl-pyrazol-4'-yl)-pyrazoline
 A mixture of 1-(p-chlorophenyl)-3-(1' ,N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one (4.28 g, 0.01 M), phenyl hydrazine (1.08 g, 0.01 M)
in 25 ml methanol was refluxed for 12 hrs. in the presence of basic catalyst
piperidine. The reaction mixture was poured on to crushed ice. The product was
isolated and crystallised from dioxan. Yield 58%, m.p. 123oC (C32H27ClN4O;
Required : C, 74.05; H, 5.24; N, 10.79;  Found : C, 74.01; H, 5.19; N, 10.73%).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 3.
(E) Antimicrobial  activity of  1,N-phenyl-3-aryl-5-(1' ,N-phenyl-3'-o-
ethoxyphenyl-pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 3.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-PHENYL-3-(p-TOLYL)-5-(1' ,N-PHENYL-3'-O-
ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 457.1
 478.3
 497.6
 515.0
 594.0
 642.3
 686.6
 759.9
 777.3
 810.0
 914.2
 958.6
1018.3
1056.9
1124.4
1180.4
1215.1
1247.9
1280.6
1315.4
1365.5
1407.9
1452.3
1500.5
1552.6
1596.9
2229.6
2856.4
2912.3
3024.23406.1
 Observed
Alkane C-H str. (asym.) 2912 2975-2950 520
-CH3 C-H str. (sym.) 2856 2880-2860   “
C-H i.p.def. (asym.) 1452 1470-1435   “
C-H o.o.p. def. (sym.) 1365 1390-1370   “
Aromatic C-H  str. 3024 3080-3030 521
C=C str. 1552 1585-1480   “
C-H i.p. def. 1124 1125-1090   “
C-H o.o.p. def   810     835-810   “
Pyrazole C=N str. 1596 1630-1590 522
moiety C-N str. 1056 1230-1020   “
Ether C-O-C str. (asym.) 1247 1275-1200 520
C-O-C str. (sym.) 1018 1075-1020   “
Pyrazoline C=N str. 1596 1630-1590 524
                                       (overlapped)
C-N str.                                 1180 1230-1020   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
N N
OCH3
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 1 ,N-PHENYL-3- (p-CHLOROPHENYL)-5- (1 ' ,N-
PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.24-1.28 3H triplet -OCH2CH3  JCH3=6.70
2. 2.97-3.05 1H double CHl  Jlk=16.92
doublet  Jlj=6.47
3. 3.46-3.56 1H double CHk  Jkl=16.95
doublet  Jkj=12
4. 4.02-4.09 2H quartet -OCH2CH3  JCH2=6.80
5. 5.43-5.45 1H multiplet CHj        -
6. 7.00-7.10 3H multiplet Ar-Hf, Ar-Hg        -
Ar-Hh
7. 7.18-7.23 2H multiplet Ar-Hc, Ar-Hi        -
8. 7.33-7.63 9H multiplet Ar-Hnn’, Ar-Hbd        -
Ar-Ho,p,q,r,s
9. 7.69-7.80 4H multiplet Ar-Hae,Ar-Hmm’        -
  10. 8.32 1H singlet CHx
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EXPANDED AROMATIC REGION
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051015202530
ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(III) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However, the maximum activity was observed in compounds bearing
R=4-chlorophenyl, 3-nitrophenyl and 4-nitrophenyl substituents against B.coccus.
The significant activity was observed in compounds bearing R=4-bromophenyl and
4-nitrophenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R=4-fluoro
phenyl and 4-nitrophenyl against E.aerogenes. In case of P.aeruginosa all the
compounds were least active except R=4-hydroxyphenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal
strain. However mild activity was shown by the compounds bearing R=bromophenyl
against A.niger.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    PART - II
STUDIES ON
CYANOPYRIDONES
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INTRODUCTION
Biosignificant pyridones form a component in a number of useful drugs
and are associated with many biological, pharmaceutical and therapeutic activities.
Pyridones, with a carbonyl group at position-2 (I) have been subject of extensive
study in the recent years. Synthetic pyridone derivatives contribute much to the
searchable literature of pyridone derivatives in huge libraries owing to their wide
applicability in different fields.
some 2-pyridones, which are pharmacologically important are as under: eg.
amrinone(II), ciclopirox(III) and methylprylon (IV).
SYNTHETIC ASPECTS
Different methods for preparation of cyanopyridones are as under.
1. Rajul Jain et. al.103 have synthesised 3-cyano-2-pyridone by the reaction
of various enones with cyanoacetamide in presence of t-BuOK in DMSO
under O2 atmosphere.
N
H
O
N
N
H
NH2
O
N
H
CH3
O
N
H
O
O
C2H5
C2H5
CH3
(I)
(II) (III) (IV)
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2. K. Follkers and S. A. Harris104 have synthesised 3-cyano-2-pyridone by
the condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
3. W. Russel Bowman et. al.105 have synthesised cyanopyridone from 2,6-
dibromopyridine in presence of chlorotrimethylsilane and sodium iodide
in acetonitrile.
4. G. Simchen and G. Entenmann106 have synthesised 2-pyridones in which
the ring nitrogen comes from a nitrile group in acyclic precursor. Addition
of HCl to the nitrile produces an imidoyl chloride which can cyclize.
5. M. A. Sluyter and co-workers107 have prepared fused 2-pyridones.
R1
O
R2 R3
+
NH2
O
N
t-BuOK
DMSO
O2
N
H
R1
R2
R3
N
O
R1, R2, R3= Alkyl
(V)
N
H
CH2OC2H5
N
O
CH3
O
NH2
N
+
O
CH3
H5C2OH2C
O
(VI)
NBr Br N
H
O
N
(VII)
67Cyanopyridone...
MECHANISM
 The addition reaction between ethylcyano acetale and α,β-unsaturated ketone give
cyanopyridone via Michael addition. Here, α, β-unsaturated compound is known as acceptor
and active methylene group containing compound known as addender. It involves
nucleophillic addition of carbanion to the C=C of the acceptor.
THERAPEUTIC IMPORTANCE
Pyridone derivatives have been found to possess variety of therapeutic
activities as shown below.
(a) Anticancer108
(b) Antimicrobial109
(c) Angitensin II antagonist110
(d) Antiviral111
(e) Anti HIV112
(f) Herbicidal113
(g) Pesticidal114
R
O
R' CNCH2COOC2H5
CH3COONH4
NH
O
N
R
R'
NH2
O
N
R
OH
R'
OC2H5
O
N
R
OH
R'
NH3
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Mukhtar H. K. and co-workers115 have prepared 2-pyridone derivatives (VIII)
which possess insecticidal and pesticidal activity. M. K. Morishita and co-workers116
have synthesised m-(2-oxo-1,2-dihydropyridyl) urea derivatives (IX) possessing
cholesterol acyltransferase (ACAT) inhibitory activity and are useful for the
treatment of hyperlipidemia and arteriosclerosis.
Peter and co-worker117 have prepared pyridinylmethyl substituted pyridines
and pyridones as angiotensin II antagonists. H. Posnes118 synthesised 2-pyridones
and 2-pyrones as physiologically active compounds. Collins et. al.119 prepared
heteroaryl pyridones as GABA α2/α3 ligands (X).
Pednekar120  synthesised some new fused 2-pyridones as useful heterocyclic
moieties as they possess a broad spectrum of biological activities such as antiviral,
CNS depressant, bactericidal and ulcer inhibitor. Moreover several co-workers have
prepared 2-pyridones as S3 site of thrombin inhibitor121, herbicidal122, SH2 domain
inhibitor123, antimicrobial124, GABA-A receptor125 and antiinflammatory126 agent.
N
H
N
S
O
N
R
S
R1
N
O
CH3
O
N
H
O
Bu
N
H
Pr
Pr
R, R1 = Aryl
(VIII) (IX)
NH
O
X
Z
Y
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Upadhyay et. al.127 have synthesised cyanopyridine derivatives which showed
antifungal and antileishmanial activities. E. Amer128 prepared-3-cyano-2-pyridone
derivatives (XI) showing high antimicrobial activity. Anticancer activity of 2-
pyridones (XII) have been reported by Abou El-Fotooh and coworkers129.
M. G. Nizamuddin and co-workers130 have prepared cyanopyridone derivatives
(XIII) and reported their antifungal activity.
Nersesyan K. et. al.131 have investigated some new cyanopyridones
possessing genotoxic activity in murine cells and antitumor activity. Xi Qi et. al.132
have investigated cyanopyridones useful as phosphatase inhibitors and studied their
biological activities.
N
H
N
N
H
NN
O O
Ar Ar
N
N
H
O
O
N
Et
X
X
X = F, Cl, Br(XI) (XII)
R R1
O
NH
N
N
O
O
N
R, R1 = Aryl(XIII)
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Darcq Michael. G. et. al.133 have discovered some new cyanopyridone
derivatives which showed in vitro HCV NS5B inhibitory activity and exhibited
IC50 in the range of 0.0001 µM to 100 µM. Their pharmaceutical compositions are
useful for treating HCV infections. Smith Terence134 has documented cyanopyridones
useful as AMPA receptor antagonists for the treatment of dimyelinating disorders
and neurodenerative disease.
Recently, Devdas B. et. al.135 have synthesised pyridone derivatives (XIV)
which are useful for treating diseases and conditions caused or exacerbated by
unregulated P38 MAP kinase and/or TNF activity, such as inflammation, ischemia,
viral infections and autoimmune diseases. Wang S. and co-workers136 have prepared
2-pyridone containing tricyclic alkaloid derivatives as potential inhibitors of tumor
cell proliferation by regioselective intramolecular N- and C-acylation of 2-pyridone.
A novel series of pyridone inhibitors has been identified through pharmacophore
analysis as potent and selective VLA-4 integrin antagonists by Jason Witherington
et. al.137 Jiang Q. and co-workers138 have identified a series of novel pyridones as
kinase inhibitors of ALK.
Thus the important role played by cyanopyridone nucleus for various
physiological activities prompted us to explore cyanopyridone chemistry by
synthesising its derivatives bearing pyrazole ring systems of therapeutic importance,
in order to achieving compounds having better drug potential which has been
described as under.
SECTION - I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO
-4-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-
6-ARYL-1,2-DIHYDRO-2-PYRIDONES
O N
Br O
Et
(XIV)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-(1',N-
P H E N Y L - 3 ' - O - E T H O X Y P H E N Y L - P Y R A Z O L - 4 ' - Y L ) - 6 - A RY L - 1 , 2 -
DIHYDRO-2-PYRIDONES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives by the
condensation of chalcones of type-(I) with ethylcyano acetate in the presence of
ammonium acetate as shown under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
R
O
CN-CH2-COOC2H5
CH3COONH4
N
N
OCH3
NH
O
R
N
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-(1',N-
P H E N Y L - 3 ' - O - E T H O X Y P H E N Y L - P Y R A Z O L - 4 ' - Y L ) - 6 - A RY L - 1 , 2 -
DIHYDRO-2-PYRIDONES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-chlorophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis  of  3-cyano-4-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-
6-(p-chlorophenyl)-1,2-dihydro-2-pyridone
 A mixture of 1-(p-chlorophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-
4'-yl)-2-propen-1-one (4.28 g, 0.01 M), ethylcyano acetate (1.13 g, 0.01 M) and
ammonium acetate (6.16 g, 0.08 M) in absolute alcohol was refluxed for 12 hrs.
The reaction mixture was poured on to crushed ice and product was isolated and
crystallised from ethanol. Yield 74%, m.p. 260oC (C29H21ClN4O2; Required : C,
70.66; H, 4.29; N, 11.37;  Found : C, 70.59; H, 4.23; N, 11.32%).
TLC solvent system : Acetone : Benzene (3 : 7).
Similarly other substituted pyridones have been prepared. The physical
data are recorded in Table No. 4.
(E) Antimicrobial  activity of  3-cyano-4-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-6-aryl-1,2-dihydro-2-pyridones
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 4.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-O-ETHOXYPHENYL-
PYRAZOL-4'-YL)-6-(p-ANISYL)-1,2-DIHYDRO-2-PYRIDONE
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 520
-CH3 C-H str. (sym.) 2854 2880-2860   “
C-H i.p.def. (asym.) 1458 1470-1435   “
C-H o.o.p. def. (sym.) 1392 1390-1370   “
Aromatic C=C str. 1535 1585-1480 521
C-H i.p. def. 1095 1125-1090   “
C-H o.o.p. def   821     835-810   “
Pyrazole C=N str. 1604 1630-1590 522
moiety C-N str. 1157 1230-1020   “
Ether C-O-C str. (asym.) 1242 1275-1200 520
C-O-C str. (sym.) 1037 1075-1020   “
Pyridone ring C≡N str. 2214 2240-2120 522
C=O str. 1639 1760-1655   “
N-H str. 3413 3450-3250   “
N-H def. 1604 1650-1580   “
                                       (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 459.0
 516.9
 559.3
 597.9
 682.8
 756.0
 821.6
 914.2
 948.9
1037.6
1095.5
1157.2
1242.1
1284.5
1334.6
1392.5
1458.1
1496.7
1535.2
1604.7
1639.4
2214.1
2854.5
2923.9
3078.2
3413.8
N
N
OCH3
NH
O
N
OCH3
74Cyanopyridone...
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-O-ETHOXYPHENYL-
PYRAZOL-4'-YL)-6-(p-CHLOROPHENYL)-1,2-DIHYDRO-2-PYRIDONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.08-1.13 3H triplet -OCH2CH3 JCH3=6.80
2. 3.78-3.86 2H quartet -OCH2CH3 JCH2=6.96
3. 6.18 1H singlet CHy        -
4. 6.92-6.95 1H doublet Ar-Hf Jfg=8.29
5. 7.10-7.15 1H triplet Ar-Hg        -
6. 7.24-7.27 2H doublet Ar-Hkk’ Jkj=8.60
7. 7.32-7.39 3H multiplet Ar-Hh, Ar-Hb        -
Ar-Hd
8. 7.43-7.54 3H multiplet Ar-Hc, Ar-Ha        -
Ar-He
9. 7.61-7.64 2H double Ar-Hi Jig=1.20
doublet Jih=7.24
  10. 7.82-7.85 2H doublet Ar-Hjj’ Jjk=7.99
  11. 8.75 1H singlet CHx        -
N
N
OCH3
NH
O
N
Cl
ab
c
d e
f
g
h
i
x
y
k'
k
j
j'
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EXPANDED AROMATIC REGION
N
N
OCH3
NH
O
N
Cl
ab
c
d e
f
g
h
i
x
y
k'
k
j
j'
IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-O-ETHOXYPHENYL-
PYRAZOL-4'-YL)-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R    C=O str.
      4a C6H5- 1648 2210
4b 4-NH2-C6H4- 1642 2212
4c 4-Cl-C6H4- 1644 2217
4d 4-Br-C6H4- 1640 2215
4e 4-F-C6H4- 1643 2219
4f 2-OH-C6H4- 1649 2212
4g 4-OH-C6H4- 1645 2218
4h 4-OCH3-C6H4- 1639 2214
4i 4-CH3-C6H4- 1642 2217
4j 3-NO2-C6H4- 1647 2215
4k 3-NO2-C6H4- 1641 2213
4l 2-C4H3S- 1638 2216
C≡N str.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been concluded that all the compounds
were mildly active against Gram positive bacterial strains except R=4-aminophenyl
which showed highest activity against B.coccus and R=2-thienyl which showed
highest activity against S.aureus.
In case of Gram negative bacterial strains, the compounds bearing R=4-
chlorophenyl, 4-methoxyphenyl and 3-nitrophenyl have exhibited significant activity
against E.aerogenes. The compounds bearing R=phenyl, 4-chlorophenyl and 4-
bromophenyl have shown maximum activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger. Maximum activity
was shown by the compounds bearing R=4-fluorophenyl, 4-tolyl and 4-nitrophenyl.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    PART - III
STUDIES ON
ISOXAZOLES
81Isoxazole...
INTRODUCTION
Isoxazole is a  π-excessive five membered heterocyclic compound containing
two hetero atoms oxygen and nitrogen at position-1 and position-2. In 1888, Claisen
first suggested an isoxazole structure (I), for a product from the reaction of 1,3-
diketone with hydroxylamine139. There after Claisen and his students form a strong
foundation for the chemistry of isoxazoles.
Isoxazoles possess typical properties of an aromatic system but under
certain reaction conditions, particularly in reducing or basic media, it becomes
highly labile. A huge role in the chemistry of isoxazoles was played by Quelico in
1946, when he began to study the formation of isoxazoles from nitrile N-oxides
and unsaturated compounds140.
Well known sulpha drug sulphamethoxazole, antiinflammatory drug
isoxicam, antitumor drug acivicin bears isoxazole type of nucleus which suggest
isoxazoles and it’s derivative have better therapeutic values in the field of medicinal
chemistry.
O
N
(I)
NH2 SO2NH
N O
CH3
O
N
HCl
CH
NH2
COOH
Sulfamethoxazole
Acivicin
(antitumor)
(antibacterial)
S
N
OH
CH3
CONH
N O
CH3
O O
Isoxicam
(antiinflammatory)
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SYNTHETIC ASPECT
The construction of isoxazole ring was carried out by the reaction of hydroxylamine
with α,β-unsaturated carbonyl compounds, which results in an oxime formation which
later on undergo cyclisation.
1. Fanshawe and Crawley141 prepared isoxazoles (II) from chalcones.
2. Issa Yavari and Loghman Moradi142 have synthesised isoxazoles (III)
from activated acetylenes and alkyl 2-nitroethanoates in the presence of
triphenylphosphine.
3. Mark Lautens and Amelie Roy143 have prepared isoxazoles from N-aceto
acetyl Derivatives.
4. Jesse P. Waldo and Richard C. Larock144 have sythesised isoxazole derivatives
via Electrophilic cyclisation.
R
R'
O
+
NH2
OH
.HCl
KOH
O
N
R'
R
(II)
O
N
ROC
CO2R'ROC
PPh3 +
COR
COR
+ R'O NO2
O
PhCH3
reflux
(III)
R1
R2
O
NH2OMe.HCl
R1
R2
N
OMe
E-X
O
N
R1
R2
E
E-X = I2, ICl, Br2, PhSeBr
(IV)
83Isoxazole...
MECHANISM
Here the reaction proceeds via the formation of an oxime which undergoes
cyclisation in buffer media. Reaction takes place between hydroxylamine and
chalcone.
THERAPEUTIC IMPORTANCE
Isoxazoles have various medicinal applications such as:
(a) Antiinflammatory145-148
(b) Anticonvulsant149,150
(c) Muscle Relaxant150,151
(d) Antipyretic152
(e) Anticholestermic153
(f) Antibacterial154,155
(g) Antidiabetic156
(h) Nematocidal157
(i) Fungicidal158,159
(j) Antiviral160
(k) Herbicidal161,162
(l) Anthelmintics163
(m) Antileukemic164
(n) Antitumor165
(o) Hypoglycemic166
(p) Analgesic167
A novel class of isoxazole derivatives with high affinity for the central
nicotinic cholinergic receptor have been prepared by Olesen P. H. et. al.168
Batu O. S. and co-workers169 have synthesised isoxazole derivatives possessing
R
R'
O R
R'
N OH
O
N
R
R'
NH2OH
84Isoxazole...
bronchodilator activity. Lee J. H. et. al.170 have synthesised 4,5-dihydro-7H-
pyrano[3,4-c] isoxazole derivatives and tested for antifungal activity in which one
of the compound showed high fungicidal activity against rice blast, providing more
than 90% control of the disease at 2 ppm level.
R. Ulrich et. al.171 have synthesised isoxazole derivatives and reported their
adrenergic antagonist activity. Daniele Simoni and Manlio Tolomeo172 have
designed a novel g1 phase targetting isoxazole derivative (V) which is structurally
related to arotinoids, was found to possess interesting apoptotic activity. Hongwu
He et. al.173 have prepared Methyl-1-(5-methyl-isoxazole-3-oxy-acetoxy)alkyl-
methyl phosphinates and tested for their plant growth regulatory activity.
Qi Chuanmin et. al.174 have discovered isoxazoles as herbicidal. Wu
Chengde et. al.175 have synthesised isoxazole derivatives as endothelin activity
modulators. Some of the compounds exhibited IC50 values of 0.0015 ± 0.0014 µΜ
for ETA receptors and 0.324 ± 0.78 µΜ for ETB receptors. Caroline and co-workers176
have studied isoxazoles which have been used for the clinical trials of asthama.
Nantermet P. G. et. al.177 have discovered a non peptidic isoxazole derivative
reported as antagonist of the human platelet thrombin receptor (PAR1). Optimization
of the 5-amino-3-arylisoxazole resulted in an approximate 100 fold increase in
potency. Romero J. R.178 has discovered a isoxazole derivative named pleconaril
as a antipicornaviral agent and promising drug for the treatment of enteroviral and
rhinoviral infections.
CH3CH3
CH3 CH3
CH3
O
N
HO2C
Cis form
(V)
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 Bo Liu et. al.179 have discovered novel isoxazole carboxamides (VI) as
growth hormone secretagogue receptor (GHS-R) antagonists. Patrizia Cali et. al.180
have synthesised & reported isoxazoles (VII) as peptide deformylase inhibitors and
potential antibacterial agent.
Isoxazole derivatives as a novel class of activators for chloride conductance
in the cystic fibrosis transmembrane conductance regulatorn  protein has been
identified by Robert Sammelson et. al.181 Andres J. I. et. al.182 have discovered a
new series of centrally active tricyclic isoxazoles combining serotinin (5-HT)-
reuptake inhibition with alpha(2)-adreno-ceptor blocking activity which is described
as potential antidepressant. Bente Frolund et. al.183 have reported tetrazolylisoxazole
amino acids as ionotropic glutamate receptor antagonists (VIII).
CONTRIBUTION FROM OUR LABORATORY
V. B.  Pate l  and co-workers184 have prepared isoxazoles  bear ing
sulphonamide moiety and reported their antimicrobial activity. R. C. Khunt, A. R.
Parikh and co-workers185 have prepared isoxazole derivatives which possess
antimicrobial  activity. Rajeev Doshi and co-workers186 have discovered isoxazoles
as a new class of potential antitubercular agents. Ketan Hirpara et. al.187 have
N
O
O
NH
CH3
R'
R
(VI) R, R' = Aryl/Alkyl (VII)
N O
S R
O
NH
OH
R= Alkyl/Aryl
N
N
NH
N
O
NCH3
HOOC
H2N
O
(VIII)
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synthesised isoxazoles as antitubercular agents. A. V. Dobaria et. al.188 have
described the isoxazole derivatives and their use as antimicrobial agents. B. P.
Kansagar et.  al.189 have demonstrated various isoxazole and tested their
antimicrobial activity.
Recently, H. S. Yathirajan et. al.190 have synthesised novel 4-(5-methyl-3-
phenylisoxazole-4-yl) benzene-sulfonamide ethylmethyl ketone used as non-sterodial
intiinflammatory drug. Makarov V. A. and co-workers191 have discovered the novel
[(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus-2
and coxsackievirus B3 replication. Bryan H. Norman et. al.192 have reported
cyclohexyl-linked tricyclic isoxazoles as potent and selective modulators of the
multidrug resistance protein (MRP1)(IX). Jie-Fei Cheng et. al.193 have prepared
isoxazole derivatives as MCD inhibitors. Wiles J. A. and co-workers194 have
prepared des fluoroisothiazolo pyridone derivatives which exhibited antibacterial
activity and inhibitory activities against DNA gyrase and topoisomerase IV.
With a view to getting better therapeutic value, it was contemplated to
synthesise isoxazole derivatives incorporating pyrazole as parent molecule, to
enhance the overall activity of resulting compounds which have been described
as under.
SECTION - I  :  SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-
 5-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-
 ISOXAZOLES
N
N
O
CH3
Cl
O
NHO
Ph
(IX)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1' ,N-
PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-ISOXAZOLES
With a view to achieving better drug potency, isoxazole derivatives of type
(V) have been prepared by the condesation of chalcone of type (I)  with
hydroxylamine hydrochloride in the presence of sodium acetate in glacial
acetic acid. The chalcones were synthesised by the condensation of 1,N-phenyl-3-
o-ethoxyphenyl-4-formyl pyrazole with various aromatic ketones.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
R
O
NH2OH.HCl
CH3COONa
N
N
O N
R
OCH3
Type (V)    R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1' ,N-
PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-ISOXAZOLES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-bromophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis of 3-(p-bromophenyl)-5-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-isoxazole
A solution of anhydrous sodium acetate (1.46g, 0.02 M) in a minimum
amount of hot acetic acid was added to a solution of hydroxylamine hydrochloride
(1.4 g, 0.02 M) in ethanol (20 ml). This solution was added to a solution of
1-(p-bromophenyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-2-propen-1-
one (4.73 g, 0.01 M) in ethanol (25 ml). The mixture was heated under reflux on
waterbath for 12 hrs. The product was isolated and recrystallised from ethanol.
Yield 68%, m.p. 119oC (C26H20BrN3O2; Required : C, 64.21; H, 4.14; N, 8.64;
Found : C, 64.14; H, 4.08; N, 8.58%).
TLC solvent system : Acetone : Benzene (2 : 8).
Similarly other substituted isoxazoles have been prepared. The physical
data are recorded in Table No. 5.
(E) Antimicrobial  activity of  3-aryl-5-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-isoxazoles
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 5.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(p -ANISYL)-5-(1' ,N-PHENYL-3'-O-ETHOXY
PHENYL-PYRAZOL-4'-YL)-ISOXAZOLE
 
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 447.5
 507.2
 688.5
 752.2
 806.2
 829.3
 867.9
 904.6
 958.6
 997.1
1029.9
1058.8
1101.3
1174.6
1220.9
1249.8
1303.8
1353.9
1382.9
1436.9
1498.6
1558.4
1596.9
2835.2
2931.6
3004.9
3060.8
3336.6
 Observed
Alkane C-H str. (asym.) 2931 2975-2950 520
-CH3 C-H str. (sym.) 2835 2880-2860   “
C-H i.p.def. (asym.) 1436 1470-1435   “
C-H o.o.p. def. (sym.) 1382 1390-1370   “
Aromatic C-H str. 3060 3080-3030   “
C=C str. 1558 1585-1480 521
C-H i.p. def. 1101 1125-1090   “
C-H o.o.p. def   829     835-810   “
Pyrazole C=N str. 1596 1630-1590 522
moiety C-N str. 1174 1230-1020   “
Ether C-O-C str. (asym.) 1249 1275-1200 520
C-O-C str. (sym.) 1058 1075-1020   “
Isoxazole C=C str. 1558 1580-1550   “
                                      (overlapped)
C=N str. 1596 1470-1460   “
                                      (overlapped)
N-O str.   806     850-800   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
O
N
OCH3
OCH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-(p-BROMOPHENYL)-5-(1',N-PHENYL-3'-O-
ETHOXYPHENYL-PYRAZOL-4'-YL)-ISOXAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.14-1.19 3H triplet -OCH2CH3  JCH3=6.90
2. 4.04-4.07 2H quartet -OCH2CH3  JCH2=6.90
3. 7.02-7.10 1H triplet Ar-Hg        -
4. 7.17-7.19 1H doublet Ar-Hf Jfg=8.40
5. 7.36-7.41 1H triplet Ar-Hh        -
6. 7.45-7.49 2H triplet Ar-Hc, Ar-Hi        -
7. 7.54-7.60 2H triplet  Ar-Hb, Ar-Hd        -
8. 7.66 1H singlet CHy        -
9. 7.76-7.79 2H doublet Ar-Hjj’ Jjk=8.40
  10. 7.85-7.97 4H multiplet Ar-Ha, Ar-He        -
Ar-Hkk’
  11. 9.34 1H singlet CHx        -
N
N
O
N
OCH3
Br
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j
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k
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y
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EXPANDED AROMATIC REGION
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ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that all the isoxazole
derivatives (V) markedly inhibit the growth of Gram positive bacteria and also
Gram negative bacteria.
All compounds showed moderate activity against Gram positive bacteria.
However, maximum activity was observed in compounds bearing R=4-hydroxy
phenyl, 4-methoxyphenyl and 4-nitrophenyl against B.coccus whereas R=4-methoxy
phenyl against S.aureus.
In case of Gram negative bacterial strains, the maximum activity was
displayed by the compounds bearing R=4-fluorophenyl and 4-methoxyphenyl
against E.aerogenes. While the compounds with R=phenyl, 4-aminophenyl,
2-hydroxyphenyl and 4-methoxyphenyl have shown considerable activity against
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All compounds exhibited mild activity against A.niger except compound
bearing R=4-hydroxyphenyl and 4-nitrophenyl which showed good activity against
A.niger.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    PART - IV
STUDIES ON
THIOSEMICARBAZONES
96Thiosemicarbazone...
INTRODUCTION
Thiosemicarbazones, also known as amino derivatives of thiourea, have
found their way into almost every branch of chemistry, commercially they are used
as dyes, photographic films, plastic and in textiles industry.
Thiosemicarbazone derivatives are of special importance because of their
versatile biological and pharmacological activities. Thiosemicarbazone derivatives
have found applications in drug development for the treatment of central nervous
system disorders, of bacterial infections, as well as analgesic and antiallergic agent.
They are potent intermediates for the synthesis of pharmaceutical and bioactive
materials.
The clinically active drug methisazone and related compounds have shown
activity against DNA viruses, principally the orthopoxviruses, both in vitro and
in vivo.
SYNTHETIC ASPECTS
The reaction between thiosemicarbazide and carbonyl compounds have
aroused a great attention because of the interesting nature of resulting compounds
for their uses in medicine.
N
CH3
O
N NH
C S
NH2
Methisazone
97Thiosemicarbazone...
Different methods for the synthesis of thiosemicarbazones are available in
literature.195-198
1. A. B. Tomchin199 has synthesised thiosemicarbazones by the recyclisation
of 2-amino-5-(2-aminoaroyl)-1,3,4-thiadiazoles.
2. Perumal Y. and co-workers200 have prepared thiosemicarbazones by the
condensation of 6-chlorobenzothiazolyl-2-thiosemicarbazide with aldehydes
or ketones.
3. A. K. Bhatt and co-workers201 have synthesised thiosemicarbazones by the
condensation of chalcones with thiosemicarbazide.
THERAPEUTIC IMPORTANCE
Thiosemicarbazones exhibit a wide range of physiological and biological
activities such as,
(a) Anticancer202,203
(b) Anticonvulsant204
(c) Antiherpes205
(d) Antimalarial206
(e) Antirheumatics207
(f) Antifungal208,209
(g) Antibacterial210
(h) Antitumor211,212
(i) Anthelmintics213
S
N N
O
R1 
R 
NH2
NH
R2 N
H
N
NH
NH
S
R2
R1 
R CH3COOH
N
SCl
NH
NH
NH2S
Aldehyde/ketone
gl. acetic acid
N
SCl
NH
NH
NS
R
R'
(I)
(II)
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W. Deteng and co-workers214 have prepared thiosemicarbazones (III) and
documented their usefulness as sodium channel blockers.
Magalhaes N. et. al.215 have synthesised some new thiosemicarbazones the
compounds were tested in vitro by the Lepidium Sativum Phytotest. All compounds
showed higher activity than 5-fluorouracil, an anticancer compound used as
reference. Toxicity and fungiocity of some novel thiophene-2-carboxaldehyde
thiosemicarbazones have been evaluated by Teoh-Siang-Guan et. al.216
Rajasekaran  A.  and co-workers217 have  prepared  some new
thiosemicarbazone (IV) and reported their antimicrobial activity. Duffy K. J.218
prepared some new thiosemicarbazones (V) and reported them as thrombopoietin
mimetics. Some of the compounds were found to stimulated the proliferation of
BAF-3/TPO-responsive human cell lines with full TPO efficacy and with EC50
values below 100 nM.
N
OCl
N
NH NH2
S
(III)
N
H
N
NH
NH2 S
F F
NH NH
O
N
OH
OH OH
(IV) (V)
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 The  new th iosemicarbazones  (VI)  der ived f rom 2-(1-adamantyl
carbonyl)pyridine and 1-acetyladamantane were synthesized and evaluated for their
inhibitory effect on tumor cell proliferation and their antiviral and antimicrobial
activity by Nicolas Kolocouris et. al.219
Amir Azam et. al.220 have synthesised 5-nitrothiophene-2-carboxaldehyde
thiosemicarbazone derivatives and reported their antiprotozoal activity. In which
some of the compounds exhibited better antitrichomonial and antiamoebic activity
respectively comparable to that of metronidazole. The inhibitory effect of several
thiosemicarbazones was investigated against Junin Virus, an arenavirus agent of
Argentine haemorrhagic fever by Damonte E. B. et. al.221 Hugo Cerecetto et. al.222
have reported in vitro growth inhibition activity of thiosemicarbazone derivatives
against the protozoan parasite Trypanosoma cruzi, the causative agent of American
trypanosomiasis.
Sznol M. et. al.223 have suggested 3-amino pyridine-2-carboxaldehyde
thiosemicarbazone as a new and potent inhibitor of ribonucleotide reductase,
increases the cellular uptake, DNA incorporation and cytotoxicity of gemcitabine
in tumor cell line. P. Yogeeswari and co-workers224 have synthesised 6-substituted
benzoth iazoly l -2- th iosemicarbazone  der iva t ives  and screened for  the i r
anticonvulsant activity in maximal electroshock induced seizure and subcutaneous
pentylenetetrazole induced seizure models in mice and neurotoxicity was also
observed.
N NH
R
S
NH2
R = 2-pyridyl, methyl(VI)
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R. Kiplin Guy et. al.225 have reported the synthesis and evaluation of a
series of thiosemicarbazones  as potential inhibitors of cysteine proteases relevant
to parasitic diseases. Alexandre J.S. Goes and co-workers226 have prepared some
new thiosemicarbazone (VII) and reported their anti-Toxoplasma gondii activity.
Dharmarajan Sriram and co-workers227 have prepared isatin 2-thiosemicarbazone
derivatives (VIII) and reported their anti-HIV activity in HTLV-IIIB strain in the CEM
cell line. Wei-xiao Hu and co-workers228 have synthesised thiosemicarbazone
derivatives and reported their anticancer activity.
Thus the important role displayed by thiosemicarbazones for various
physiological activities prompted us to prepare a series of thiosemicarbazones
having pyrazole nucleus as parent molecule which has been described as under.
SECTION : I SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL
-3-(1',N-PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-
2-PROPENE-1-THIOSEMICARBAZONES
N
NH
S
NH
R 
O2N
N
O
N NH
S
N
CH3
CH3
N
R1
R2
(VII)
(VIII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1' ,N-
PHENYL-3' -O-ETHOXYPHENYL-PYRAZOL-4' -YL)-2-PROPENE-1-
THIOSEMICARBAZONES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of thiosemicarbazones. To further assess the potential of such a class
of compounds, thiosemicarbazones of type (VI) have been prepared by the
condensation of 1-aryl-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-2-propen-
1-ones with thiosemicarbazide.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
R
O
gl. CH3COOH
N
N
N
OCH3
R
NH S
NH2
NH2
S
NH NH2
Type (VI)   R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1' ,N-
PHENYL-3'-O-ETHOXYPHENYL-PYRAZOL-4'-YL)-2-PROPENE-1-
THIOSEMICARBAZONES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(C) Synthesis of 1-(p-tolyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propen-1-one
See [A] Part-I, Section-I (C).
(D) Synthesis  of  1-(p-tolyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-
yl)-2-propene-1-thiosemicarbazone
A mixture of 1-(p-tolyl)-3-(1',N-phenyl-3'-o-ethoxyphenyl-pyrazol-4'-yl)-
2-propen-1-one (3.42 g, 0.01 mol) and thiosemicarbazide (0.91g, 0.01 mol) in
ethanol (20ml.) containing catalytic amount of acetic acid was refluxed for 8 hrs.
on water bath. The reaction mixture was poured on to crushed ice and product was
isolated and recrystallised from ethanol. Yield 52%, m.p. 90oC (C28H27N5OS;
Required : C, 69.83; H, 5.65; N, 14.54;  Found : C, 69.76; H, 5.58; N, 14.50%).
TLC solvent system : Acetone : Benzene (3 : 7).
Similarly other substituted thiosemicarbazones have been prepared. The
physical data are recorded in Table No. 6.
(E) Antimicrobial  activity of  1-Aryl-3-(1',N-phenyl-3'-o-ethoxyphenyl-
pyrazol-4'-yl)-2-propene-1-thiosemicarbazones
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 6.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1- (p - TOLYL )-3- (1 ' ,N-PHENYL-3' -O -ETHOXY
PHENYL-PYRAZOL-4'-YL)-2-PROPENE-1-THIOSEMICARBAZONE
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 534.2
 607.5
 688.5
 750.3
 833.2
 866.0
 958.6
1024.1
1062.7
1126.4
1176.5
1215.1
1249.8
1384.8
1407.9
1452.3
1498.6
1581.5
1598.9
2860.2
2958.6
3060.8
3406.1
 Observed
Alkane C-H str. (asym.) 2958 2975-2950 520
-CH3 C-H str. (sym.) 2860 2880-2860   “
C-H i.p.def. (asym.) 1452 1470-1435   “
C-H o.o.p. def. (sym.) 1384 1390-1370   “
Aromatic C-H str. 3060 3080-3030   “
C=C str. 1498 1585-1480 521
C-H i.p. def. 1126 1125-1090   “
C-H o.o.p. def   833     835-810   “
Pyrazole C=N str. 1598 1630-1590 522
moiety C-N str. 1215 1230-1020   “
Ether C-O-C str. (asym.) 1249 1275-1200 520
C-O-C str. (sym.) 1062 1075-1020   “
Thiosemi- N-H str. 3406 3400-3200   “
carbazone C=N str. 1581 1630-1580   “
C=S str. 1176 1220-1050   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
N
OCH3
NH S
NH2
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 1-(P-TOLYL)-3-(1',N-PHENYL-3'-O-ETHOXYPHENYL-
PYRAZOL-4'-YL)-2-PROPENE-1-THIOSEMICARBAZONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.25-1.29 3H triplet -OCH2CH3 JCH3=6.80
2. 2.42 3H singlet Ar-CH3        -
3. 4.04-4.09 2H quartret -OCH2CH3 JCH2=6.80
4. 7.00-7.02 1H doublet Ar-Hf Jfg=8.40
5. 7.05-7.09 1H triplet Ar-Hg        -
6. 720-7.24 1H doublet CHz (vinylic) Jzy=15.6
7. 7.24-7.27 3H multiplet Ar-Hjj’, -NH        -
8. 7.31-7.35 1H triplet  Ar-Hh        -
9. 7.40-7.45 1H multiplet Ar-Hc        -
  
10. 7.46-7.50 2H triplet Ar-Hb, Ar-Hd        -
  11. 7.52-7.54 1H double Ar-Hi Jig=1.60
doublet Jih=7.20
  12. 7.72-7.76 1H doublet CHy (vinylic) Jyz=16
  13. 7.79-7.83 4H triplet Ar-Hkk’,Ar-Ha,        -
Ar-He
  14. 8.33 1H singlet CHx        -
N
N
N
OCH3
NH S
NH2
CH3
ab
c
d e
f
g
h
i
x
y
z
j
k
j'
k'
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EXPANDED AROMATIC REGION
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CONCLUSION
ANTIBACTERIAL ACTIVITY
I t  has  been  concluded f rom the  exper imenta l  da ta  tha t  a l l  the
thiosemicarbazone derivatives (V) significantly inhibit the growth of Gram positive
bacteria and also Gram negative bacteria.
Maximum activity was observed in compounds bearing R=phenyl, 4-
nitrophenyl ,2-thienyl against B.coccus and R=4-aminophenyl, 4-chlorophenyl
against S.aureus.
In case of E.aerogenes significant activity was displayed by compounds
bearing R=phenyl, 4-methoxyphenyl and 4-nitrophenyl. Compounds with R=phenyl
and 4-chlorophenyl showed highest activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
The compounds were tested against fungal species A.niger .  It has been
concluded that all the compounds were active against A.niger. Maximum activity
was displayed by the compounds bearing R=phenyl, 4-chlorophenyl, 4-hydroxy
phenyl and 2-thienyl.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    PART - V
STUDIES ON
IMIDAZOLINONES
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INTRODUCTION
The five membered heterocyclic ring system 5-oxo-imidazoline (I) has two
nitrogen atoms at 1- and 3-positions and a carbonyl group at 5-position.
2-Substituted-5-oxo-imidazolines have been reported for the first time in
1888. A. W. Hoffman229 have prepared 2-methyl-5-imidazoline (lysidine) by heating
N1-diacetylethylene diamine in a stream of dry hydrogen chloride. A. Ladenburg230
have prepared the same compound by fusing two equivalents of sodium acetate
with one equivalent of ethylene diamine dihydrochloride.
Acetolactate synthase (ALS), the first enzyme in the biosynthetic pathway
of leucine, isoleucine and valine is inhibited by imidazolinone herbicides like
imazapic, imazaquin.
SYNTHETIC ASPECTS
Various methods have been reported for the synthesis of imidazolinones in
literature.231 Aminolysis of oxazolone with amine leads to the formation of
imidazolinones which has been reported in literature.232
N
N
H
O
(I)
N
N
NH
CH3 COOH
O
CH
CH3
CH3
CH3
N
N
NH
COOH
O
CH
CH3
CH3
CH3
Imazapic Imazaquin
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1. Hisato Takeuchi et. al.233 have synthesised imidazolinones by the reaction
of azido substituted imides with triphenylphosphine or tributylphosphine.
2. Allimony et. al.234 have synthesized new imidazolinone derivatives by
conventional method.
3. Feng-Jun-Cai et. al.235 have reported 5-imidazolinone derivatives by microwaves
irradiation.
4. Jean Michel Lerestif et. al.236 have synthesised imidazolinone from α-amino
ester.
5. A. Saxena et. al.237 have synthesized new imidazolinones.
MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acryclic acids obtained from the
condensa t ion  of  aza lac tone  and pr imary  amines  can  be  conver ted  in to
imidazolinones as shown in equation (III). The ring closure can be affected under a
variety of conditions. Substituted anilides have been converted to imidazolinone
derivatives by the action of POCl3.
R3
N R1
N3 R2
O O
N R1
R2
R3
O
Ph3P or Bu3P
(II)
O
N
O
Ar
Cl
NHNH2
O
Dry Pyridine
ONH
N
N
O
Ar
Cl
(III)
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THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazoline and phenotolamine as adrenergic blocking agents. Various imidazolinones
are known to exhibit a broad spectrum of biological activities such as,
(a) Anticonvulsant238,239
(b) Sedative and hypnotics240
(c) Bactericidal241,242
(d) Fungicidal243,244
(e) Antiparkinsonian245,246
(f) Anthelmintic247
(g) Antihistaminic248
(h) Anticancer249,250
(i) Antidiabetic251
(j) Antitubercular252
(k) Potent CNS depressant253,254
(l) Insecticidal255
(m) Antiviral256
(n) Hypertensive257
(o) Antiinflammatory258-260
(p) Glucagon antagonists261
(q) Antimicrobial262
(r) Thrombin inhibitor263
N
O
O
X
R
R'-NH2 NH
X
R
O
NHO
R'
POCl3
N
N O
R
R'X
R’-NH2, DryC5H5N/Abs. C2H5OH, K2CO3
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Kolhe Vishnu264 have investigated anti-AIDS, anticancer, antibacterial and
antifungal activity of imidazolinones. Antifungal activity of imidazolinones towards
Aspergillus fumigutus is investigated by T. Kitazaki et . al265. Lacroix Guy et. al.266
have synthesised 5-imidazolinones as possible agrochemical fungicide. Rama
Sharma and co-workers267 have formulated 5-oxo-imidazolines possessing
potential antimicrobial activity.
Imam Hidayat  et .  al .268 have reported ALS-inhibi tory act ivi ty of
imidazolinones. Keun-Jin Oh et. al.269 have investigated some imidazolinone
derivatives which possess the enzymatic activity as well as the binding affinity for
the cofactor FAD (Flavin adenine dinucleotide). Solankee A.270 have synthesised
some imidazolinone derivatives (IV) and screened for their anticancer activity.
Muchii Dalsuke et. al.271 have synthesised new imidazolones as a telomerase
inhibitors and antitumor agents. Zhong Jin272 has found imidazoline derivatives
(V) as cytoxic towards several tumor cell lines.
N
N
N
N
O
Ph
CH3CH3
Ph
OAr
(IV)
NH
N
N
NH3CO
OCH3
OCH3N
O
CH3
O
(V)
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Irene M. L. et. al.273 have investigated some imidazolinone derivatives
possessing antireteroviral activity. Lee Jin Ho et.  al.274 have formulated
imidazolinones which showed an excellent anticancer effect by inhibiting an activity
of FTase (protein farnesyl transferase).  Ozaki Satoshi et. al.275 have reported
imidazolinones useful as analgesic, antagonists against tolerance to narcotic
analgesics typified by morphine, agents for the treatment of obesity and drugs for
ameliorating brain function. El-Sayed A. S.276 has synthesised imidazolinone
derivatives (VI) and screened for their antibacterial and antifungal activities.
CONTRIBUTION FROM OUR LABORATORY
 Dr. H. H. Parekh et. al.277 suggested imidazolinones as a antitubercular
and  anticancer (VIII) agent.
H. H. Parekh and co-workers278 have synthesised 5-oxo-imidazolines as
novel bioactive compounds derived from benzimidazole. P. H. Patel and co-workers279
have discovered imidazolines bearing 2-amino-thiazole moiety as antimicrobial
agents.
O
O2N
N
N
O
SO2NHR1
R
(VI)
N
N
NH NH
S
OO
CH3
O
CH3
Ar
(VIII)
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Khunt, Datta and Parikh280 have reported 5-oxo-imidazolines as biologically
active agents. Kanjaria and co-workers281 have described imidazolinones as potential
antimicrobial agents. Satyen Patel and co-workers282 have synthesis imidazolines
as biologically active agents.
Joshi H. et. al.283 have synthesised imidazolinones as potent anticonvulsant agents.
Parikh et. al.284 have reported 4-(4’-arylidene-2’-phenyl-5’-oxo-imidazolin-1’-yl)-
benzophenone and screened for their antimicrobial activity.
Recently, C. Alister and co-workers285 have documented herbicidal activity
of  imidazol inone der ivat ives .  E.  Jayachandran et .  a l .286 have reported
imidazolinones as antimicrobial agents. Aleksey Vasiliev et. al.287 have synthesised
imidazolinone derivatives (VII) and reported their herbicidal activity. Imidazolinone
derivatives as acetohydroxyacid  synthase (AHAS) inhibitors hve been suggested
by Tan S. and co-workers288.
The development of efficient and selective synthesis of imidazolinones has
attracted increasing attention because they often bring about unique pharmacodynamic
activities. In search of biologically potent imidazolinone derivatives, it was
considered worthwhile to synthesise imidazolinones which have been described as
under.
SECTION I     : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-
ARYL-2-PHENYL-4-(1’ ,N-PHENYL-3’-O-ETHOXY-
PHENYL-4’-PYRAZOLYLMETHINE)-IMIDAZOLIN-
5-ONES
N
N
H
N
O
CH3
CH3
CH3
COOHR
R'
(VII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-PHENYL-
4-(1’,N-PHENYL-3’-O-ETHOXYPHENYL-4’-PYRAZOLYLMETHINO)-
IMIDAZOLIN-5-ONES
Imidazol inone  der iva t ives  possess  var ie t ies  of  b io logica l  and
pharmacological properties. Here, we report the synthesis of some new 5-oxo-
imidazolines of type (VII). The strategy employed for the synthesis of desired
compounds involved the condensation of azlactones with different aromatic amines
shown as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
O
N O
N
N
OCH3
N
N
R
O
R-NH2
Pyridine
Type (VII)     R = Aryl
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N
N
OCH3
CHO
CO
NH COOH
N
N
OCH3
O
N O
+
(CH3CO)2O
CH3COONa
R-NH2
Pyridine
N
N
OCH3
N
N
R
O
REACTION SCHEME
Type - (VII) R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-PHENYL-
4-(1’,N-PHENYL-3’-O-ETHOXYPHENYL-4’-PYRAZOLYLMETHINO)-
IMIDAZOLIN-5-ONES
(A) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(B) Synthesis of 2-Phenyl-4-(1',N-phenyl-3'-o-ethoxyphenyl-4'-
pyrazolylmethino)-oxazolin-5-one
A mixture of 1,N-phenyl-3-o-ethoxyphenyl-4-formyl pyrazole (2.92 g,
0.01M), acetic anhydride (7.6ml, 0.075M), sodium acetate (2.0 g, 0.025M) and
hippuric acid (4.4g, 0.025M) was heated on waterbath for 4 hrs. Resulting mass
was poured onto crushed ice, filtered, washed with hot water and crystallised
from ethanol. Yield 73%, m.p. 146oC, (C27H11N3O3 : Required C : 74.47; H : 4.86;
N: 9.65; Found C : 74.41; H : 4.79; N : 9.61%).
TLC solvent system : Ethylacetate : Hexane (2 : 8)
(C)  Synthesis of 1,N-p-Tolyl-2-phenyl-4-(1',N-phenyl-3'-o-ethoxyphenyl-
 4'-pyrazolylmethino)-imidazolin-5-one
A mixture of 2-Phenyl-4-(1',N-phenyl-3'-o-ethoxyphenyl-4'-pyrazolylmethino)-
oxazolin-5-one (4.35 g, 0.01M) and p-toludine (1.07g, 0.01M) in dry pyridine (20 ml)
was refluxed for 12 hrs. Resulting mass was poured on to crushed ice and neutralised
with HCl, filtered and crystallised from DMF. Yield,  63%, m.p. 156oC (C34H28N4O2
: Required C: 77.84; H: 5.38; N: 10.68; Found : C: 77.76; H: 5.31; N: 10.64%). TCL
solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly other imidazolin-5-ones have been prepared. The physical data
are recorded in Table No. 7.
(D)  Antimicrobial activity of 1,N-aryl-2-phenyl-4-(1’,N-phenyl-3’-o-ethoxy
phenyl-4’-pyrazolylmethino)-imidazolin-5-ones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 7.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-(p-TOLYL)-2-PHENYL-4-(1',N-PHENYL-3'-O-
ETHOXYPHENYL-4'-PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONE
-10.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
110.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 567.0
 605.6
 688.5
 729.0
 756.0
 833.2
 885.3
1028.0
1053.1
1105.1
1164.9
1213.1
1253.6
1286.4
1363.6
1434.9
1500.5
1596.9
1629.7
1672.1
1706.9
2879.5
2964.4
3053.1
 Observed
Alkane C-H str. (asym.) 2964 2975-2950 520
-CH3 C-H str. (sym.) 2879 2880-2860   “
C-H i.p.def. (asym.) 1434 1470-1435   “
C-H o.o.p. def. (sym.) 1363              1390-1370   “
Aromatic C-H str. 3053 3080-3030   “
C=C str. 1500 1585-1480 521
C-H i.p. def. 1105 1125-1090   “
C-H o.o.p. def.   833     835-810   “
Pyrazole C=N str. 1596 1630-1590 522
moiety C-N str. 1213 1230-1020   “
Ether C-O-C str. (asym.) 1286 1275-1200 520
C-O-C str. (sym.) 1053 1075-1020   “
Imidazolinone C=O str. 1706 1770-1655   “
ring C=N str. 1629 1650-1550   “
C-N str. 1253 1260-1220   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
OCH3
N
N O
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 1,N-p-TOLYL-2-PHENYL-4-(1',N-PHENYL-3'-O-
ETHOXYPHENYL-4'-PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.34-1.38 3H triplet -OCH2CH3 JCH3=6.8
2. 2.42 3H singlet Ar-CH3        -
3. 4.11-4.16 2H quartet -OCH2CH3 JCH2=6.8
4. 7.02-7.09 4H multiplet Ar-Hf, Ar-Hg        -
Ar-Hn, Ar-Hp
5. 7.20-7.22 2H doublet Ar-Hjj’ Jjk=8
6. 7.33-7.37 4H multiplet Ar-Hm, Ar-Ho        -
Ar-Hq, CHy
7. 7.40-7.46 2H multiplet Ar-Hh, Ar-Hc        -
8. 7.48-7.52 2H triplet  Ar-Hb, Ar-Hd        -
9. 7.56-7.61 3H multiplet Ar-Hi, Ar-Ha        -
Ar-He
  10. 7.87-7.89 2H doublet Ar-Hkk’ Jkj=8
  11. 9.29 1H singlet CHx        -
N
N
OCH3
N
N O
CH3
ab
c
d e
f
g
h
i
x y
j'
j
k
k'
m
n
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q
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EXPANDED AROMATIC REGION
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N O
CH3
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q
IR SPECTRAL STUDY OF 1,N-ARYL-2-PHENYL-4-(1',N-PHENYL-3'-O-ETHOXY
PHENYL-4'-PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONES
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R     C=O str.
      7a C6H5- 1714
7b 4-Cl-C6H4- 1716
7c 3,4-(Cl)2-C6H3- 1720
7d 4-Br-C6H4- 1712
7e 4-F-C6H4- 1715
7f 3-Cl,4-F-C6H3- 1712
7g 2-OCH3-C6H4- 1710
7h 4-OCH3-C6H4- 1718
7i 2-CH3-C6H4- 1716
7j 4-CH3-C6H4- 1706
7k 2-NO2-C6H4- 1712
7l 4-NO2-C6H4- 1714
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ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been observed that all the compounds of
type (VII) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having R=4-chloro
phenyl, 4-methoxyphenyl and 4-nitrophenyl against B.coccus. The compounds
bearing R=4-bromophenyl ,2-methoxyphenyl and 4-tolyl have highly inhibited the
growth of S.aureus.
Compounds with R=4-fluorophenyl ,2-methoxyphenyl and 4-nitrophenyl
showed significant activity against E.aerogenes. While the compounds bearing
R=4-bromophenyl, 4-fluorophenyl and 2-tolyl have fairly inhibited the growth
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were active against A.niger. Maximum activity was
observed by the compounds bearing R=3,4-dichlorophenyl, 2-tolyl, 4-tolyl and
4-nitrophenyl.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    PART - VI
STUDIES ON
α-ARYLAMINONITRILES
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INTRODUCTION
Nitriles are reported to possess various therapeutic activities, but due to their
high toxicity, they have low therapeutic importance. The term ‘Nitrile’ was first introduced
by Febung289 in 1844. The first synthesis of nitrile has been reported by Wohler and
Liebig290 in 1832 and Poleuze291 in 1834. They are very much useful as intermediates
for various products such as acrylonitrile for plastic, synthetic rubber and fibers,
phthalonitrile for dye stuff.
SYNTHETIC ASPECTS
Few recent methods for the preparation of nitriles are as mentioned below.
1. Barahman Movassagh and Salman Shokri292 have prepared nitriles from aryl/
alkyl aldehydes on treatment with NH2OH.HCl and KF/Al2O3 in one pot.
2. Masanori Hatsuda and Masahiko Seki293 have synthesised nitriles through
cyanation of aryl/heteroaryl bromides employing heterogeneous Pd/C.
3. Florencio Zaragoza294 has suggested method for preparation of nitriles from
alcohols.
(III)
R OH Me3P
CN
+
I
_
+
(i) DIPEA, EtCN
(ii) H2O
R
CN
(II)
Ar-Br + Zn(CN)2
Pd/C, Zn, ZnBr2, PPh3
DMA
Ar-CN
R-CHO
NH2OH.HCl, KF/Al2O3
DMF/ 100 C
R-CN
R = Alkyl or aryl(I)
128Nitrile...
4. Stephen A. Dibiase et. al.295 have synthesised E-& Z-cinnamonitrile from
aryl aldehyde or ketones in presence of acetonitrile and potassium hydroxide.
MECHANISM
The mechanism of nitrile formation is shown as under.
Reaction between CN and aldehyde is a type of nucleophilic substitution
reaction. From the above reaction, it can be seen that a nucleophile (CN) attacks
on the carbonyl carbon of aldehyde and yields cyanohydrin which reacts with amine
to yield nitrile derivatives.
THERAPEUTIC IMPORTANCE
They shows various therapeutic activities which are described as under.
(a) Antihypertensive296
(b) Antimicrobial297
(c) Antihypoxic298
(d) Antiinflammatory299
(e) Antiarrythemic300
(f) Central nervous system agent301
(g) Fungicidal302
(h) Pesticidal303
O
H
R
+ CN
O
CN
R
H
OH
CN
H
R
R1-NH2
-H2O
NH
CN
H
R
R1
H+
. .
_
Ar-CHO
Ar
N
CH3CN
KOH
(IV)
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Yogihara  and co-workers304 have  documented ant imicrobia l  and
antiinflammatory activity of nitriles. Nosyrava et. al.305 have formulated novel
nitriles possessing muscle relaxant activity. Valmajer Juliya et. al.306 have tested
some new nitriles as anticonvulsant agent. Collin Xavier and co-workers307 have
synthesised nitriles and screened for their antifungal activity. Shibata yasushi and
co-workers308 have reported nitriles as insecticides. Parlo Sanna et. al.309 have
synthesised nitriles (V) and screened for their antitubercular activity.
Bernard M. et. al.310 have investigated nitriles as thromboxane receptor
antagonists. Suzana Jovanovic et. al.311 have suggested antiestrogenic activity of
some nitrile derivatives. Iwanowicz E. J. et. al.312 have synthesised nitriles (VI)
and found preventing and treating IMPDH associated disorders, such as transplant
rejection and autoimmune disease.
 Ian J. S. Fairlamb et. al.313 have prepared nitrile derivatives and tested for
their antimicrobial activity. M. Hiroshi et. al.314 have investigated some new nitriles
and studied their pesticidal and marin antifouling activity. Cyanoguanidine
derivative (VII) has been synthesised and reported as inhibitors of mitochondrial
F, FO, ATPase by A. Karnails et al.315 Nurolaini Kifli et. al.316 have discovered
nitriles and reported their antiviral activity.
N
N
N
N
NH2
N N
N
NH2
S
CH3
N
(V)
(VI)
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CONTRIBUTION FROM OUR LABORATORY
F. M. Bharmal and H. H. Parekh317 have synthesised newer acetonitriles (VIII)
bearing quinoline moiety and tested them as antimicrobial agent.
Recently, Marion Nipper et.  al.318 have prepared nitriles useful as
antimicrobial agent. Miroslav Otmar et. al.319 have formulated nitriles possessing
antiproliferative activity. S. Srinivasan et. al.320 have investigated nitriles which
showed antimicrobial activity. Olivier Nicolas and co-workers321 have discovered
nitrile derivatives possessing moderate antimalarial activity. Guohua Zhao et. al.322
have reported Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Jon
Bondebjerg and co-workers323 have identified a potent and selective inhibitor of
human dipeptidyl peptidase I by using a dipeptide nitrile scaffold.
Looking to the interesting properties of nitriles, we have synthesised some
new nitriles, which have been described as under.
SECTION - I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF α-
ARYLAMINO-(1’,N-PHENYL-3’-O-ETHOXYPHENYL-
PYRAZOL-4’-YL)-ACETONITRILES
CF3
F3C
N
N
NH N
CN
NH
Cl Cl
N
CH3
Cl
NH
R
N
(VII)
(VIII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-(1’,N-
PHENYL-3’-O-ETHOXYPHENYL-PYRAZOL-4’-YL)-ACETONITRILES
In view of therapeutic activities of nitriles, it was contemplated to synthesise
some new nitriles in search of agents possessing higher biological activity. Nitriles
of type (VIII) have been synthesised by the reaction of 1,N-phenyl-3-o-
ethoxyphenyl-4-formyl pyrazole with different aromatic amines in the presence of
potassium cyanide and glacial acetic acid at 0-50C.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N
N
OCH3
NH
R
N
N
N
OCH3
CHO
R-NH2, KCN, 0-5  C
gl. CH3COOH
Type (VIII)     R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-(1’,N-
PHENYL-3’-O-ETHOXYPHENYL-PYRAZOL-4’-YL)-ACETONITRILES
(A) Synthesis  of  o-Ethoxyphenylhydrazone
See [A] Part-I, Section-I (A).
(B) Synthesis of 1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
(C) Synthesis of α-p-Anisylamino-(1’,N-phenyl-3’-o-ethoxyphenyl-pyrazol-
4’-yl)acetonitrile
1,N-Phenyl-3-o-ethoxyphenyl-4-formyl pyrazole (2.92 g, 0.01M) dissolved
in ethanol (25ml) was added to potassium cyanide (0.64g, 0.01M) dissolved in
water (15 ml) followed by glacial acetic acid (12 ml). The contents were then stirred
for 5 minutes to form cyanohydrin at 0oC. p-Anisidine (1.23g, 0.01M) dissolved in
methanol was added to the reaction mixture, contents were stirred at room
temperature for 24 hrs. The content was poured onto curshed ice. The solid product
was filtered and crystallised from ethanol. Yield 58%, m.p. 146oC (C26H24N4O2;
Required : C, 73.56; H, 5.70; N, 13.20;  Found : C, 73.48; H, 5.63; N, 13.16%).
TLC solvent system : Acetone : Benzene (1 : 9).
Similarly other substituted nitriles have been prepared. The physical data
are recorded in Table No. 8.
(D) Antimicrobial activity of α-arylamino-(1’,N-phenyl-3’-o-ethoxyphenyl-
pyrazol-4’-yl)-acetonitriles
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 8.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF α-p-ANISYLAMINO-(1’,N-PHENYL-3’-O-ETHOXY
PHENYL-PYRAZOL-4’-YL)-ACETONITRILE
40.0
50.0
60.0
70.0
80.0
90.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 464.8
 513.0
 588.2
 694.3
 759.9
 837.0
 912.3
 962.4
 997.1
1064.6
1159.1
1232.4
1307.6
1411.8
1448.4
1502.4
1535.2
1595.0
2216.1
2854.5
2916.2
3060.8
3355.9
 Observed
Alkane C-H str. (asym.) 2916 2975-2950 520
-CH3 C-H str. (sym.) 2854 2880-2860   “
C-H i.p.def. (asym.) 1448 1470-1435   “
Aromatic C-H str. 3060 3080-3030   “
C=C str. 1502 1585-1480 521
C-H i.p. def. 1064 1125-1090   “
C-H o.o.p. def   837     835-810   “
Pyrazole C=N str. 1595 1630-1590 522
moiety C-N str. 1159 1230-1020   “
Ether C-O-C str. (asym.) 1232 1275-1200 520
C-O-C str. (sym.) 1064 1075-1020   “
                                                              (overlapped)
Nitrile C≡N str. 2216 2240-2220 523
N-H str. 3355 3350-3200   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N
OCH3
NH
N OCH3
134Nitrile...
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF α-p-CHLOROPHENYLAMINO-(1’,N-PHENYL-3’-O-
ETHOXYPHENYL-PYRAZOL-4’-YL)ACETONITRILE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.27-1.32 3H triplet -OCH2CH3 JCH3=6.81
2. 3.90-3.97 2H quartret -OCH2CH3 JCH2=6.92
3. 5.51 1H singlet CHy                   -
4. 6.39-6.42 2H doublet Ar-Hkk’ Jkj=8.76
5. 6.85-6.88 2H doublet Ar-Hf Jfg=8.21
6. 6.97-7.02 1H triplet Ar-Hg        -
7. 7.19-7.22 2H doublet Ar-Hbd Jba=8.73
8. 7.29-7.35 2H multiplet  Ar-Hh, Ar-Hc        -
9. 7.38-7.43 2H triplet Ar-Ha, Ar-He        -
  10. 7.48-7.50 1H double Ar-Hi Jig=1.52
doublet Jih=7.43
  11. 7.66-7.69 2H doublet Ar-Hjj’ Jjk=7.99
  12. 8.17 1H singlet CHx        -
N
N
OCH3
NH
N Cl
ab
c
d e
f
g
h
i
x
j'
j
k
k'
y
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EXPANDED AROMATIC REGION
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IR SPECTRAL STUDY OF α-ARYLAMINO-(1’,N-PHENYL-3’-O-ETHOXY PHENYL-
PYRAZOL-4’-YL)ACETONITRILE
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
Sr.
No. R
      8a C6H5- 2212
8b 4-Cl-C6H4- 2210
8c 3,4-(Cl)2-C6H3- 2217
8d 4-Br-C6H4- 2205
8e 4-F-C6H4- 2218
8f 3-Cl,4-F-C6H3- 2214
8g 2-OCH3-C6H4- 2210
8h 4-OCH3-C6H4- 2216
8i 2-CH3-C6H4- 2213
8j 4-CH3-C6H4- 2218
8k 2-NO2-C6H4- 2215
8l 4-NO2-C6H4- 2208
C≡N str.
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ZONE OF INHIBITION IN mm B.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that the compounds bearing
R=phenyl, 2-methoxyohenyl and 2-nitrophenyl have displayed good activity against
B.coccus. The compounds bearing R=3,4-dichlorophenyl, 2-methoxyphenyl and
4-methoxyphenyl have show considerable activity against S.aureus.
In case of gram negative bacterial strains all the compounds were inactive
against E.aerogenes except the compound bearing R=3-chloro4-fluorophenyl. While
the compounds bearing R=phenyl, 3-chloro4-fluorophenyl, 2-methoxyphenyl and
4-nitrophenyl showed significant activity against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited moderate to poor activity against the tested
species. However, the compounds having R=4-chlorophenyl and 4-methoxyphenyl
displayed highest activity against A.niger.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    [B]
STUDIES ON
TRIAZOLES
141Triazole...
INTRODUCTION
The chemistry of triazole derivatives have attained greater interest because of
its useful applications in medicine, agriculture and industrial chemistry. In five membered
ring systems, the presence of three nitrogen heteroatoms defines an interesting class of
compounds, the triazoles. Triazole molecule is having following isomers 1,2,3-triazoles
or υ-triazoles (I) and 1,2,4-triazoles or s-triazoles (II).
The chemistry of 1,2,4-triazoles deal briefly in the earlier publications.324,325
The first 1,2,4-triazole derivative was synthesised by Bladin in 1885. An alternative
name for the ring system, introduced in 1889 by Andreocci is pyrrodiazole, which is
regarded as a member of a class of compounds analogous to pyrrole. A most intensive
investigation of the chemistry of 1,2,4-triazoles, especially by Andreocci’s successors in
Rome, followed the pioneering work of these two investigators.
From about 1925 to 1946 little interest was shown in this field. The discovery
that certain types of triazoles were capable of inhibiting fog formation in photographic
emulsions and that others were useful herbicides and convulsants led to a renewed
attention, particularly by the chemical industry, to both simple and fused triazole systems.
1,2,4-Triazole derivatives are also used as analytical reagents326, photographic
chemicals327 and in polymer328 synthesis. All triazoles are of synthetic origin and there
is no report of detection of this ring system in nature.
N
H
N
N
N
NH
N
N
H
N
N
N
NH
N
(I)
(II)
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SYNTHETIC ASPECTS
Several methods have been reported in the literatures for the preparation of
1,2,4-triazoles. Some procedures for synthesising 1,2,4-triazoles have been described
as under.
1. Reid and Heindel329 reported that the reaction of aryl acid hydrazide with
CS2/KOH and hydrazine hydrate furnished triazoles.
2. C. S. Andotra and Sukhbinder Kaur330 synthesised triazole pyrimidine by
the reaction of aromatic acid with substituted hydrazino pyrimidine.
3. Ahmad S. Shawali et. al.331 synthesised 1,2-bis (4-amino-5-mercapto-4H-
1,2,4-triazol-3-yl) ethane by heating succinic acid with two molar equivalents of
carbonothioic dihydrazide in an oil bath at 170oC.
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4. Kap-Sun Yeung et. al.332 synthesised 3,5-disubstituted 1,2,4-triazoles from
nitriles and hydrazides in presence of basic catalyst.
5. Shin-ichi Nagai333 synthesised triazole by the reaction of thiosemicarbazide
with formic acid in presence of acetic anhydride.
6. Zhang Zivi et al.334 prepared 1,2,4-triazoles by the addition reaction of
2,4-dichlorophenoxy aceticacid hydrazide with R-CO-NCS gave aroyl
thiosemicarbazides, cyclization of this in H2O in the presence of alkaline
catalyst gives triazoles.
THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good activity
are listed as under.
R1 C N +
R2
O
NH
NH2
N
N NH
R1 R2
K2CO3, n-BuOH
150 C
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ClCl
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N
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N
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N
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Literature survey reveals that various 1,2,4-triazole derivatives have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological activities.
3-Amino-1,2,4-triazole was the first triazole manufactured on large scale from
aminoguinidine formate useful as neutral herbicides335. Therapeutic activity of 1,2,4-
triazoles are listed as under.
(a) Antiinflammatory336
(b) Diuretic337
(c) Antiviral338
(d) Antihypertensive339
(e) Anthelmintics340
(f) Bactericidal341
(g) Anticonvulsant342
(h) Herbicidal343
(i) Fungicidal344
(j) Antimicrobial345
(k) Anticancer and anti-HIV346
(l) Plant growth regulator347
(m) Antileishmanial348
(n) Antitumor349
Emilsson Haakan350 have prepared several triazoles as anti hypertensive agent
and reported 4-amino-3-hydrazino-5-isopropyl-4H-1,2,4-triazole was the most potent
one with 20% reduction in blood pressure at 40 µmol/kg. A series of new 1H-1,2,4-
triazole derivatives was synthesised and evaluated in vitro for activity against various
DNA and RNA viruses by E. De Clercq et. al.351
Various 4-N-substituted amino-4H-1,2,4-triazole derivatives were synthesized
and evaluated for aromatase-inhibitory activity (in vitro) and for pregnant mare serum
gonadotropin (PMSG)-induced estrogen synthesis-inhibitory activity by Fujikura T. and
co-workers352. Yanagisawa I. et. al.353 have synthesised pyrazolo[1,2,4]-triazole
derivatives which was orally active in rats, and produced a dose-dependent decrease in
blood pressure when administered orally to conscious furosemide-treated dogs.
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Chen Y. and Lu. K.354 have synthesized 4’-demethyl-podophyllotoxin derivatives
possessing 4β-S-triazoles and their antitumor activities were screened in vitro against
HL-60, BGC-823, BcaP, KB and K562 cells. Bignon Eric et. al.355 have reported
N-triazolyl-2-indole carboxamides and their use as CCK-A agonists. These compounds
have partial or total CCK-A receptor agonist activity and are useful for treating eating
problem, obesity, tardive dyskinesia and disorders of the gastrointestinal sphere (VIII).
Demirbas A. et. al.356 have prepared new derivatives of 1,2,4-triazole and
screened for their antitumor activities using cell lines derived from human solid tumors.
Mevlut Ertan and co-workers357 have synthesised 6-benzylidenethiazolo[3,2-b]-1,2,4-
triazole-5(6H)-ones and evaluated for their antiinflammatory activity. In gastric
ulceration studies the synthesized compounds were generally found to be safe at a 200
mg/kg dose level. Sun-Qingyan et al.358 have synthesised triazole (IX) and reported
their antifungal activity.
A series of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives were
prepared and evaluated for their affinity to hV1A and selectivity vs hV2 by Akio
Kakefuda and co-workers359. In vivo evaluation in rats demonstrated that one of the
compound was selective and orally active antagonist for the V1A receptor and that its
activity was long-lasting. Fisher Karl J. et. al.360 have synthesised 1,2,4-triazole
derivatives (X) to study their pesticidal and herbicidal activity.
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Neikamura Hiroshi and co-workers361 have investigated 1,2,4-triazole
derivatives which is useful for treatment of hyperuricemia. Balkovee et. al.362 have
formulated triazoles as antidiabetic agent. Biologically active triazoles (XI) were reported
by Chepal P. V. and co-workers.363 Aoki Satosh et. al.364 have investigated triazoles
as potent cyclooxygenase inhibitors (XII).
Yaseen A. et. al.365 have prepared 1,5-dialkyl-3-(5-mercapto-4,N-aryl-1H-
1,2,4-triazol-3-yl-methylene)-1H-1,2,4-triazole which exhibited remarkable activity
against nine types of cancer and also antiviral activity. Neslihan Demirbas and his
co-workers366 have documented antimicrobial activity of some newly synthesised 1,2,4-
triazole derivatives.
Krzysztof W. et. al.367 have discovered 1,2,4-triazoles and reported their
antimycobacterial activity. Dae-Kee Kim et. al.368 have synthesised 1,2,4-triazole
derivatives and screened for their significant ALKS inhibitory activity in the luciferase
reporter assays (XIII).
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Neslihan Demirbas et. al.369 have screened triazole derivatives for their
antiinflammatory, anticancer, antituberculosis and antihypertensive acitivities. Marie-Odile
Contour-Galcera et. al.370 have synthesised 3-thio-1,2,4-triazoles (XIV) and reported
as non-peptidic human somatostatin receptor subtypes 2 and 5 agonists. K. M.
Basavaraja and co-workers371 have prepared triazole derivatives (XV) and reported
their antibacterial activity.
Recently, Guru S. Gadaginamath and co-workers372 have documented
antimicrobial activity of new triazole derivatives. Synthesis and antioxidant activities of
some 4-benzylidenamino-4,5-dihydro-1H-1,2,4-triazol-5-one derivatives has been
investigated by Haydar Yuksek et. al.373 Abbas Shafiee and co-workers374 have
synthesised 1,2,4-triazole derivatives (XVI) and screened for their antibacterial activity.
Nawal A. El-Koussi et. al.375 have prepared a series of 5-phenyl-1-(3-pyridyl)-
1H-1,2,4-triazole-3-carboxylic acid derivatives. Some of the compounds were found
to be equipotent or more potent than Indomethacin and Celecoxib as reference drugs at
two dose levels, 5 and 10 mg/kg, and they have no ulcerogenic activity.
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These valid observations led us to synthesise several derivatives like 1,3,4-
thiadiazepines, 1,3,4-thiadiazines and dihydrothiadiazoles bearing 1,2,4-triazole nucleus
in order to achieving better therapeutic agents which have been described as under.
[B] STUDIES ON TRIAZOLES
PART-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZEPINES
PART-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3,4-
THIADIAZINES
S
O SMe
N
N
N R1
R
(XVI)
R1 = NH2, NHR, SH, SMe
    PART - I
STUDIES ON
1,3,4-THIADIAZEPINES
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INTRODUCTION
1,3,4-Thiadiazepine derivatives are  one of the most active class of compounds
possesing a wide spectrum of pharmacological activities. The thiadiazepine ring system
have one sulphur atom and two nitrogen atoms at 1,3,4-position (I) in seven membered
heterocyclic ring system.
Many 1,3,4-thiadiazepine derivatives are involved in several biological process
and serves as an synthetic drugs. The thiadiazepine derivatives have stimulated considerable
research work in recent years due to their interesting biological activities.
SYNTHETIC ASPECTS
Different methods for the preparation of 1,3,4-thiadiazepine derivatives
documented in literature are as follows.
1. Brukstus A.376 have synthesised benzimidazo [2,1-b] pyrimido [5,4-f][1,3,4]-
thiadiazepine.
N
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2. R. Gururaja et. al.377 have synthesised quinolinethiadiazepine derivatives
by condensation of 2-chloro-6-substituted quinoline-3-carboxaldehyde with
thiocarbohydrazide in pyridine.
3. Balkrishna Kalluraya378 and co-workers have prepared 1,3,4-thiadiazepine
by reaction of 1,2,4-triazoles with acetylenic ketones and α-bromo chalcones.
4. K. M. Mahadevan et.  al .379 have reported microwave assisted one pot
synthesis of 8-methyl-3,6,9-triphenyl-5,6-dihydro-9H-pyrazolo [3,4-e]-[1,2,4]-
triazolo[3,4-b][1,3,4]thiadiazepines.
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5. Cl.CH2.CH2.COOH cyclised with Ph.NH.NH.CS.NH2 in refluxing AcOH
containing NaOH to give 2-amino-4-phenyl-6H,7H-1,3,4-thiadiazepin-5-one.380
6. Sinegibskaya A. D. et. al.381 have synthesised thiadiazepine by reaction of
4-amino-3-hydrazino-1,2,4-triazoline-5-thione with α-and β-dicarbonyl
compounds followed by the treatment of Br-CH2-CO-Ph.
THERAPEUTIC IMPORTANCE
Literature survey reveals that 1,3,4-thiadiazepine derivatives possess
remarkable pharmacological importance. Biological activities described are as under.
(a) Antiviral382
(b) Antidepressant383
(c) Anti psychotic384
(d) Antiarrythmic385
(e) Anti HIV386
(f) Anticonvulsant387
(g) Antitumor388
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(h) CCK antagonists389
(i) Gastrin receptor antagonists390
Non-nucleoside reverse transcripatase activity of some thiadiazepines has been
described by Artico Marino et. al.391 Rodgers James et. al.392 have suggested cyclic
urea-HIV protease inhibitors activity of some 1,3,4-thiadiazepine derivatives.
Denis Pires di Lima393 have synthesised thiadiazepines (VIII) useful as
angiotensin-converting enzyme (ACE) inhibitors and Bolos. J. et. al.394 reported them
as an important class of antihypertensive drugs.
Vice Susan F.395 have prepared di-indolo thiadiazepine compounds as
inflammations inhibitors, neoplasm inhibitors and pharmaceuticals for psoriasis
treatment. Antiinflammatory activity of new derivatives of thiadiazepines have been
patented by Puodzhyunjte B. A.396 et. al. Swati Sharma397 and co-workers have
synthesised thiadiazepine derivatives as possible potential drugs for cancer metastatics.
M. M. Ghorab and co-workers398 have suggested thiadiazepine  derivatives as
antifungal agents.
Robert J. Cherney and co-workers399 have demonstrated benzothiadiazepines
as selective tumor necrosis factor α-converting enzyme inhibitors. U. V. Laddi and
co-workers400 have prepared triazolo-thiadiazepines (IX) and tested for their
antimicrobial and antituberculosis activities. Ashutosh Singh and Nizamuddin401 have
prepared thiadiazepines (X) and reported their molluscicidal activity.
NH
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155Thiadiazepine...
M. Kidwai et. al.402 have reported thiadiazepines as potential antimicrobial agent.
R. Gururaja and co-workers403 have synthesised 1,3,4-thiadiazepines and screened
for their anthelmintic activity and antibacterial activity. Lebegue N. et. al.404 have
prepared some benzopyridothiadiazepines and evaluated them as a new class of tubulin
binders. Anshu Dandia et. al.405 have investegated benzopyrano-triazolo-thiadiazepine
(XI) as potent anti-fungal agents.
Considerable evidences has been accumulated to demonstrate the wide
applications of thiadiazepine derivatives and also 1,2,4-triazole nucleus have drawn the
attention of chemists due to diversified biological activities associated with it. In view of
these findings, it appeared of interest to synthesise newer thiadiazepine derivatives with
better potency.
SECTION - I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-
HYDROXYPHENYL)-[1,2,4]-TRIAZOLO[3,4-b]SUBSTITUTED
QUINOLINO [3’,2’-f]-1,3,4-THIADIAZEPINES
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N N
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-HYDROXY PHENYL)-
[1,2,4]-TRIAZOLO [3,4-b] SUBSTITUTED QUINOLINO [3’,2’-f]-1,3,4-
THIADIAZEPINES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of 1,3,4 thiadiazepines. To further assess the potential of such a class of
compounds, thiadiazepine derivatives of type (IX) have been synthesised by one pot
reaction of 3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole with substituted
2-chloro-3-formyl-quinolines in the presence of K2CO3.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
N
N N
N
N
S
OH R
Type (IX)     R = Aryl
157Thiadiazepine...
N N
N
NH2
SH
OH
OH COOH
OH COOC2H5
OH
O
NH NH2
OH
O
NH NH
S
SK
- +
C2H5OH
Con.H2SO4
NH2.NH2.H2O
CH3OH
C2H5OH, KOH
CS2
NH2.NH2.H2O
N
N N
N
N
S
OH
NCl
OHC
R
R
DMF
K2CO3
REACTION SCHEME
        Type - (IX)                   R=Aryl
158Thiadiazepine...
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-HYDROXYPHENYL)-
[1 ,2 ,4]-TRIAZOLO[3,4-b]SUBSTITUTEDQUINOLINO[3’ ,2’- f ] -1 ,3 ,4-
THIADIAZEPINES
(A) Synthesis of Ethyl-p-hydroxybenzoate406
A mixture of p-hydroxybenzoic acid (1.38 g, 0.01M) in ethanol (20 ml) and con.
H2SO4 (1 ml) was refluxed for 15 hrs. The reaction mixture was poured into ice cold
water. The product was isolated and crystallised from ethanol. Yield 95%, m.p. 131oC.
(B) Synthesis of p-hydroxybenzoicacidhydrazide406
A mixture of ethyl-p-hydroxybenzoate (1.66 g, 0.01M) in ethanol (20 ml) and
hydrazine hydrate (0.5 g, 0.01M) was refluxed for 7 hrs. The reaction mixture was poured
into ice cold water. The product was isolated and crystallised from DMF/Ethanol. Yield
85%, m.p. 265oC.
(C) Synthesis of Potassium p-hydroxybenzoyl dithiocarbamate
A mixture of potassium hydroxide (0.84 g, 0.015M) in absolute ethanol (25
ml), p-hydroxybenzoicacid hydrazide (1.52 g, 0.01M) and carbon disulfide (1.14ml,
0.015M) was stirred for 18 hrs. The product was precipitated by adding diethyl ether
(50 ml). Yield 90%.
(D) Synthesis of 3-Mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole
A suspension of potassium p-hydroxybenzoyl dithiocarbamate (2.66 g, 0.01M)
hydrazine hydrate (95%, 1ml, 0.02M) and water (1 ml) was refluxed with stirring for
5 hrs. The content was diluted with water and acidified with glacial acetic acid to get the
product. It was crystallised from DMF/Ethanol. Yield 53%, m.p. 257oC, (C8H8N4OS
: required : C, 46.14; H, 3.87; N, 26.90; found : C, 46.10;  H, 3.82; N, 26.84%).
TLC solvent system : Acetone : Benzene (3 : 7).
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(E) Synthesis of Substituted 2-chloro-quinoline-3-carboxaldehydes407
These were prepared by the reaction of substituted acetanilide with DMF and
POCl3 by a well known vilsmeier haack rearrangement.
(F) Synthesis of 3-(p-hydroxyphenyl)-[1,2,4]-triazolo-[3,4-b]-6-methoxyquinolino
[3’,2’-f]-1,3,4-thiadiazepine
A mixture of 3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole (2.08 g,
0.01M) 2-chloro-3-formyl-6-methoxy quinoline (2.20g, 0.01M) in dry DMF (20 ml)
and anhydrous K2CO3 (2.09 g) was refluxed at 80oC for 4 hrs. It was cooled and
poured onto crushed ice. The product was isolated and crystallised from ethanol. Yield
52%, m.p. 204oC (C19H13N5O2S ; required : C, 60.79; H, 3.49; N, 18.66, found :
C, 60.73; H, 3.45; N, 18.61%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
Similarly other substituted 1,3,4-thiadiazepines were synthesised. The physical
data are recorded in Table No. 9.
(G) Antimicrobial activity of 3-(p-hydroxyphenyl)-[1,2,4]-triazolo[3,4-b]
substituted quinolino[3’,2’-f]-1,3,4-thiadiazepines
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 9.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(p-HYDROXYPHENYL)-[1,2,4]-TRIAZOLO [3,4-b]-
6-METHOXYQUINOLINO [3’,2’-f]-1,3,4-THIADIAZEPINE
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 542.0 648.0
 748.3
 808.1
 826.4
 869.8
 933.5
1022.2
1069.5
1088.7
1104.2
1158.2
1208.3
1231.5
1324.0
1358.8
1416.6
1476.4
1492.8
1557.4
1588.3
1621.1
63 .5
2851.6
2955.7
3009.7
3438.8
 Observed
Alkane C-H str. (asym.) 2955 2975-2950 520
-CH3 C-H str. (sym.) 2851 2880-2860   “
C-H i.p.def. (asym.) 1416 1470-1435   “
C-H o.o.p. def. (sym.) 1358 1390-1370   “
Aromatic C-H  str. 3009 3080-3030 521
C=C str. 1588 1585-1480   “
C-H i.p. def. 1104 1125-1090   “
C-H o.o.p. def   826     835-810   “
Triazole C=N str. 1621 1612-1593 520
moiety C-N str. 1088 1220-1020 525
N-N str. 1022 1050-1010 520
O-H str. 3438 3550-3200 525
O-H bending 1324 1420-1330   “
Thiadiazepine C=N str. 1636 1640-1500 520
C-S-C str.   648                    700-600   “
Ether C-O-C str. (asym.) 1208 1275-1200   “
C-O-C str. (sym.) 1069 1075-1020   “
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
N
N N
N
N
S
OH
O CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-(p-HYDROXYPHENYL)-[1,2,4]-TRIAZOLO [3,4-b]-
7-METHOXYQUINOLINO [3’,2’-f]-1,3,4-THIADIAZEPINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 4.00 3H singlet Ar-OCH3          -
2. 6.94-6.97 2H doublet Ar-Haa’ Jab=8.70
3. 7.26-7.30 1H double Ar-Hf Jfg=2.34
doublet Jfe=8.92
4. 7.33-7.34 1H doublet Ar-Hg Jgf=2.32
5. 7.45 1H singlet =CHc          -
6. 7.90-7.93 1H doublet Ar-He Jef=9.11
7. 8.04-8.07 2H doublet Ar-Hbb’ Jba=8.64
8. 9.42 1H singlet Ar-Hd          -
9. 9.53 1H singlet -OH          -
N
N N
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g
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EXPANDED AROMATIC REGION
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (IX)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However, the singnificant activity was observed in compounds bearing R=6-
methoxy against B.coccus. The maximum activity was observed in    compounds bearing
R=6-chloro and 8-methoxy against S.aureus.
In case of E.aerogenes all the compounds were least active except R=7-methoxy.
The maximum activity was displayed by the compounds bearing R=7-chloro and 6-
methyl against P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds were mildly active against A.niger except compounds bearing
R=6-chloro and 6-fluoro, 7-chloro which showed good activity.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared
with standard drug viz. Greseofulvin.
    PART - II
STUDIES ON
THIADIAZINES
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INTRODUCTION
The six membered heterocyclic ring system thiadiazine has two nitrogen
atoms and one sulphur atom. These may be of four types 2H-1,2,4-Thiadiazine (I);
2H-1,2,6-Thiadiazine (II); 2H-1,3,4-Thiadiazine (III) and 2H-1,3,5-Thiadiazine
(IV).
Among these four type, 1,3,4-thiadiazine derivatives are studied well
because it exhibit various interesting biological activities408-410. In order to
develop compounds with better drug potential, it was considered of interest to
synthesis some new thiadiazines.
SYNTHETIC ASPECTS
Different methods for the preparation of 1,3,4-thiadiazine derivatives
described in literature are as follows.
1. Cyclization of 4-amino-3-mercapto-6-methyl [1,2,4] triazine-5-one with
phenacyl bromide is reported by Heravi M. M. et. al.411
NH
S
N
1
2
3
4
5
6 NH
S
N
N
S
N
N
S
N
(I) (II) (III) (IV)
N
N
N
NH2
SH O
CH3
+ Ph.CO.CH2.Br N
N
N
N
S O
CH3
Ph
(V)
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2. B. Shivarama Holla et. al.412 have synthesised triazolothiadiazines by the
cyclisation of 2,3-dibromo-1-aryl-3-[5-(p-nitrophenyl)-2-furyl]-2-propen-1-
ones and substituted 1,2,4-triazole.
3. M. Rahimizadeh et. al.413 have prepared 1,3,4-thiadiazine by the cyclisation
of 2,4-dichloro-6-methyl-5-nitro pyrimidine with dithione.
4. Ahmad S. Shawali et. al.414 have synthesised triazolothiadiazines by the
cyclisation of 4-amino-3-mercapto-5-phenyl-1,2,4-triazole and 3-chloro-2,4-
pentanedione.
O
HC
CH
O
Br
Br
R
O2N
+ N
N N
NH2
SHR'
N
N N
N
S
R'
O
NO2
R
Et3N
Dioxane
N
N
Cl Cl
CH3
NO2
+ NH NH C
S
N N PhPh
N
N
Cl
CH3
S
N
N
R
Ph
R = -N=N-Ph
(VI)
(VII)
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5. Ibrahim Yehia A. and co-workers415 have documented stereo specific
synthesis of 6,7-dihydro-5H-1,2,4-triazolo [3,4-b] [1,3,4] thiadiazines.
6. The 1,3,4-thiadiazine can also be prepared by the reaction of cyclic α-halo
ketones with 5-substituted-4-amino-4H-1,2,4-triazole-3-thiols.416
7. Bayoumy B. E. et. al.417 have designed thiadiazine ring system by the
reaction of pthalazinone triazole with phenacyl bromide.
THERAPEUTIC IMPORTANCE
Literature survey reveals that various 1,3,4-thiadiazines have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological
activities. 1,3,4-Thiadiazine derivatives possess wide range of therapeutic activities
which are as under.
N
N N
H
NH2
Ph S
+
N
H
N
N
S
N
Ph
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COCH3
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COCH3
COCH3
Cl
N
N N
N
R SH
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(X)
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(a) Antifungal418
(b) Antibacterial419
(c) Antimicrobial420
(d) Antiinflammatory421
(e) Cardiovascular422,423
(f) Analgesic424
(g) Antidepressant425
Kalluraya B. et. al.426 have reported 3-substituted-7H-6-(6-bromo-3-
coumarinyl)-s-triazolo [3,4-b] [1,3,4] thiadiazine and subjected to antibacterial
activity (XI). Lee, An Rong Taiwan427 have patented triazolo thiadiazine as
antiinflammatory agent (XII).
Jonus Rochus et. al. have prepared new thiadiazine derivative useful as
phosphodiesterase IV inhibitors428 (XIII) and cardiovascular agents.429 (XIV)
O O
Br
N
N
S
N
N
R N
N
S
N
N
R'
O
OEt
R = H, Me, Br, 4-Me-O-C6H4 R’ = Ph, 3,4,5-trimethoxy phenyl
(XI) (XII)
N
S
NZ
OR4
R3 R2 R2R1
R5
S
N N
N
CH3
R
O
C
O
OCH3
OCH3
(XIII) (XIV)
z = bond or alkylene
R1, R2=H or halo
R3, R4=OH, alkoxy, halo
R5=unsubstituted phenyl
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Ergenc Nedime and co-workers430 described the synthesis and antimicrobial
properties of new 6-aryl-3-(2-furanyl)-7H,1,2,4-triazoles [3,4-b] [1,3,4] thiadiazines
(XV). Balkrishna et. al.431 synthesised thiophene heterocycles of 6-(5-aryl-2-
thienyl)-7H-s-triazolo [3,4-b]-1,3,4-thiadiazines and reported that the chlorine
containing compounds were significantly active against E. coli. (XVI)
Arranz Esther et. al.432 have synthesised thiadiazine derivatives as non-
nucleoside reverse transcriptor inhibitors that inhibit human Immunodeficiency virus
type-I replications. Nizamuddin433 and co-workers synthesised thiadiazine
derivatives and tested their activity against Aspergillus flavus, Cephalosphorium
sacchari, Pyricylaria solani and Phytophthora inlestant at 500 ppm and 100 ppm
concentration respectively.
 Nadkarni et. al.434 have investigated anthelmintic activity of 1,3,4-
thiadiazines. Holla B. S. et. al.435 have also reported antibacterial and anticancer
activity of 1,3,4-thiadiazines. Turan-Zitouni G. et. al.436 have prepared triazolo
thiadiazines showing analgesic activity (XVII). Renuka Devi Patil and J. S.
Biradar437 have reported triazolo-thiadiazine derivatives as anthelmintic, antiin-
flammatory and anticatatonic agent (XVIII).
O
N
N N
N
S
R
N
N
N
N
S
S
NO2
R
(XV) (XVI)
R = H, Cl, Br R = H, alkyl, aryl, (aryloxy) methyl
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L. D. S. Yadav and co-workers438 have documented a convenient synthesis
of antiviral acyclic C-nucleosides incorporating 1,3,4-thiadiazine nucleus as
nucleobase. A. M. Dhiman and K. N. Wadodkar439 represents some bridgehead
nitrogen heterocycles and reported all compounds to be highly active towards
urinary tract pathogen P. mirabilis. Vicentini C. B. et. al.440 have demonstrated
thiadiazines as fungicides.
Sheena Shashikanth et. al.441 have synthesised thiadiazine derivatives and
tested their antimicrobial activity against variety of fungal and bacterial strains in
comparison to fluconazole and chloramphenicol, respectively. V. M. Patel and
K. R. Desai442 have documented antimicrobial activity of some thiadiazine
derivatives. Antimicrobial evaluation of triazolothiadiazines have been carried out
by Dawood and co-workers443. Shiradkar M. and Shivaprasad H. N.444 have
synthesised new thiadiazine derivatives and evaluated them as antibacterial,
antifungal and antitubercular agents.
The diverse biological activities have been encountered in compounds
containing triazolothiadiazine ring system. Therefore it was considered worthwhile
to synthesise 1,3,4-thiadiazine derivatives which have been described as under.
SECTION - I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-
HYDROXYPHENYL)-6-ARYL-7H-[1,2,4]-TRIAZOLO[3,4-b]-
1,3,4-THIADIAZINES
N
N N
O
N
S
R1
R2
N
H
N
NN
N
S
Ph
R
Ph(XVII) (XVIII)
R1=H, R2=Cl, NO2
R1=OH, R2=OMe
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p -HYDROXY
PHENYL)-6-ARYL-7H-[1,2,4]-TRIAZOLO[3,4-b]-1,3,4-THIADIAZINES
1,3,4-Thiadiazines represent one of the most active class of compounds
possessing a wide spectrum of biological activities, such as significant in vitro
activity against unrelated DNA and RNA viruses including polio and herpes viruses,
diuretic, antitubercular, spermicidal etc. In view of these facts, it was contemplated
to synthesis thiadiazine derivatives of type (X) by condesation of 3-mercapto-4,N-
amino-5-p-hydroxyphenyl-1,2,4-triazole with different substituted phenacyl
bromides.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
N N
N
N
S
OH
R
Type (X)     R = Aryl
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N N
N
NH2
SH
OH
OH
O
NH NH2
OH
O
NH NH
S
SK
- +
C2H5OH, KOH
CS2
NH2.NH2.H2O
RCOCH2Br
N N
N
N
S
OH
R
REACTION SCHEME
        Type - (X)                   R=Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p -HYDROXY
PHENYL)-6-ARYL-7H-[1,2,4]-TRIAZOLO[3,4-b]-1,3,4-THIADIAZINES
(A) Synthesis of Potassium p-hydroxybenzoyl dithiocarbamate
See [B] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole
See [B] Part-I, Section-I (D).
(C) Synthesis of thiadiazine 3-(p-hydroxyphenyl)-6-(p-fluorophenyl)-7H-
[1,2,4]-triazolo[3,4-b]1,3,4-thiadiazine
A mixture of 3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole (2.08
g, 0.01 M) p-fluoro-phenacyl bromide (2.17 g, 0.01 M) in dry methanol (50 ml)
was heated under reflux for 5 hrs, then cooled and neutralised with aqueous potassium
carbonate solution. The solid thus separated out was filtered, washed with water
and crystllised from ethanol. Yield 84%, m.p. 228oC (C16H11FN4OS; Required :
C, 58.89; H, 3.40; N, 17.17;  Found : C, 58.83; H, 3.33; N, 17.13%).
TLC solvent system : Ethyl acetate  : Hexane (3 : 7).
Similarly other phenacyl bromides have been condensed. The physical data
are recorded in Table No. 10.
(D) Antimicrobial activity of 3-(p-hydroxyphenyl)-6-aryl-7H-[1,2,4]-triazolo
[3,4-b]-1,3,4-thiadiazines
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 10.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(p-HYDROXYPHENYL)-6-(p-TOLYL)-7H-[1,2,4]-
TRIAZOLO [3,4-b]-1,3,4-THIADIAZINE
 Observed
Alkane C-H str. (asym.) 2983 2975-2950 520
-CH3 C-H str. (sym.) 2854 2880-2860   “
C-H i.p.def. (asym.) 1446 1470-1435   “
C-H o.o.p. def. (sym.) 1355 1390-1370   “
Aromatic C-H  str. 3066 3080-3030 521
C=C str. 1554 1585-1480   “
C-H i.p. def. 1103 1125-1090   “
C-H o.o.p. def   813     835-810   “
Triazole C=N str. 1596 1612-1593 520
moiety C-N str. 1190 1220-1020 525
N-N str. 1056 1050-1010 520
O-H str. 3417 3550-3200 525
O-H bending 1355 1420-1330   “
                                           (overlapped)
Thiadiazine N-N str. 1056 1050-1010   “
                                           (overlapped)
C-N str. 1145 1220-1020 521
C-S str. 671 700-600 525
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
0.0
20.0
40.0
60.0
80.0
100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
 457.1
 549.7
 671.2
 713.6
 769.5
 813.9
 931.6
1056.9
1103.2
1145.6
1190.0
1230.5
1301.9
1355.9
1446.5
1554.5
1596.9
2854.5
2983.7
3066.6
3417.6
N N
N
N
S
OH
CH3
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-(p-HYDROXYPHENYL)-6-PHENYL-7H-[1,2,4]-
TRIAZOLO [3,4-b]-1,3,4-THIADIAZINE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 4.24 2H singlet -CH2         -
2. 6.92-6.95 2H doublet Ar-Haa’ Jab=8.73
3. 7.50-7.58 3H multiplet Ar-Hc, Ar-He         -
Ar-Hg
4. 7.88-7.92 2H doublet Ar-Hbb’ Jba=8.70
5. 7.96-7.99 2H doublet Ar-Hdf Jdc=7.67
6. 9.73 1H singlet -OH         -
N N
N
N
S
OH
a
a'
b
b'
c
d
e
f
g
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EXPANDED AROMATIC REGION
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data it has been observed that all the compounds of
type (X) were active against Gram positive and Gram negative bacterial species.
It was observed that the compounds showed good activity against Gram
positive bacteria. Maximum activity was observed in compounds having R=4-
aminophenyl and 4-methoxyphenyl against B.coccus. The compounds bearing
R=phenyl, 4-bromophenyl and 4-methylphenyl have fairly inhibited the growth of
S.aureus.
Compounds with R=4-hydroxyphenyl and 4-nitrophenyl showed significant
activity against E.aerogenes. Almost all compounds were found to be mildly active
against P.aeruginosa except R=4-chlorophenyl and 4-methoxyphenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal
strain. However mild activity was shown by the compounds bearing R=4-fluoro
phenyl against A.niger.
The antibacterial activity was compared with standard drug viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
    [C]
STUDIES ON MICROWAVE
INDUCED SYNTHESIS OF
5,6-DIHYDRO-1,3,4-
THIADIAZOLOTRIAZOLES
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MICROWAVE INDUCED SYNTHESIS
INTRODUCTION
The term microwave was introduced just before World war-II. Microwave
radiation is a descriptive term used to identity electromagnetic waves in frequency
spectrum ranging from 1 GHz (109 Hz) to 30 GHz. These waves present several
interesting and unusual features not found in other portions of the electromagnetic
spectrum. These features make”microwaves” uniquely suitable for several useful
applications like industrial, scientific, domestic and medicinal.
In the last few years Microwave induced Organic Reaction Enhancement
(MORE) chemistry has gained popularity as a non-conventional technique for
rapid organic synthesis445 and a large number of papers has appeared proving the
synthetic utility of MORE chemistry in routine organic synthesis. It can be termed
as “e-chemistry’ because it is easy, effective, economical and eco-friendly and is
believed to be a step towards green chemistry. The advantages of microwave heating
are decreased in rate of reaction and time, cleaner reactions, easier work up and
better yields. It is also generally observed that the purity of products is improved
due to shorter reaction period at high temperature and the absence of local
overheating on the reaction walls which occurs under conventional heating.
Microwave heating is distinguished primarily by being a radiant process. Its
relationship to ordinary heat is of much interest. Regular heat rays differ in frequency
and properties. In the conventional method, heat is generated by molecular collisions
which accomplish the energy transfer while microwaves cause heating through the
absorption of energy quanta. Microwave generate instantaneous “ incore” heating
of materials, in a homogeneous and selective manner, especially those with poor
heat conduction properties.
When molecules with permanent dipole are submitted to an electric field,
they become aligned. If this field oscillates, the orientation changes at each
alternation. The strong agitation provided by the reorientation of molecules, in
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phase with the electrical field excitation, caused an intense internal heating, upto
10oC per second, when powerful waves are used.
The main interests can thus be listed as the rapid transfer of energy into the
bulk of the reaction mixture. Without inertia since only the product is heated and
the ease of utilisation. Further more, as the depth of magnitude as the wavelength
microwaves interact with substances of appreciable thickness (about 10 cm).
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute
to the heating effect when the conducting particles are in contact with a non
conducting medium, e.g. in heterogenous reactions. It is particularly convenient
that qualitatively the larger the dielecric constant, the greater the coupling with
microwaves. Thus solvents such as water, methanol, DMF, ethyl acetate, chloroform,
acetone, acetic acid, dichloromethane and R-spirit are all heated when irradiated
with microwaves. Non-polar solvents like CCl4, toluene, xylene, diethylether do
not couple and therefore do not heat with microwave irradiation.
It has been reported that the rate of variety of organic reaction such as Diels
Alder446,447, Claisen reaction448,449, Oxidation450-452, Reduction453,
Diacetylation454-456,  Esterification457 Hydrolysis of esters458,459, Doenr
Condensation460, Knoevenagel condensation461 could be enhanced by microwave
irradiation.
Generally, commercial microwave oven is being used in the chemical
laboratory at a frequency of 2450 MHz. The first application of microwave oven in
organic synthesis began very recently. By the first experiments of Gedye and Giguere,
the evidence for dramatic acceleration in some classical organic reactions
established, and these were ascribed to temperature and pressure effects, when
performed in closed Teflon vessels. The reaction can be carried out in teflon,
polystyrene and glass vessels since these are transparent to microwaves. Microwave
irradiation has also been applied for carrying out reactions in open vessels using
organic solvents. The relatively low cost of modern domestic microwave oven makes
them reasonably readily available to academic and industrial chemists.
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 Since solvents were used in these experiments, some problems with safe
operation appeared and sometimes explosion resulted. Further development
demonstrated the potential of solvent free reaction to solve these problems and to
facilitate the scale-up of preparative runs. Recently, reactions under dry conditions
using inorganic reagents are gaining more attention because of their enhance
selectivity and milder conditions than those associated with conventional
homogeneous reaction procedures. It should be noted that some of the inorganic
additives reach temperatures in excess of 1000oC very rapidly and decomposition
of materials may be problematic, therefore some precautions regarding superheating
and associated fire hazards or explosions are taken.
Detail review on “Microwave Assisted Reactions” by S. Caddick462,
involves variety of unusual chemical reactions like,
1. Aromatic Substitution Reactions
2. Alkane Functionalisation
3. Catalytic Transfer Hydrogenation
4. Oxime Synthesis
5. Radical Reactions
6. Peptide Synthesis
7. Rearrangements
8. Pericyclic Reactions
Successfully leading to the path way from non traditional approach to the
experimental setup of organic reactions, the concept of “Microwave Induced Organic
Reaction Enhancement” (MORE) chemistry has been utilized for rapid and efficient
synthesis of triazolothiadiazoles.
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INTRODUCTION
Thiadiazoles have occupied an important place in drug industry. It is
documented in the literature that thiadiazole system contains the following
members : 1,2,3-Thiadiazoles (I), 1,2,4-Thiadiazoles (II), 1,3,4-Thiadiazoles (III)
and 1,2,5-Thiadiazoles (IV). Most of the published work so far, is on 1,3,4-
Thiadiazoles.
1,3,4-Thiadiazoles were first described in 1882 by Fischer and further
developed by Busch and his co-workers. The advent of sulfa drugs and their
discovery of mesoionic compounds greatly accelerated the rate of progress in the
field of thiadiazoles.
Several thiadiazole derivatives are reported to possess pharmacological
activity whose structures are shown below.
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SYNTHETIC ASPECTS
Literature survey reveals that several publications and patents463 described
the synthesis of 1,3,4-thiadiazoles as under.
1. Sun, Xiao-Wen et al.464 and Barghash A. M.465 have synthesised 1,3,4-
thiadiazoles by the cyclisation of acid with triazole in presence of catalyst
like POCl3.
2. Alaa Hassan et. al.466 synthesised 1,3,4-thiadiazoles by the cyclization
of tetracyanoethene and 4-phenyl thiosemicarbazides.
3. Khosrow Zamani et. al.467 have prepared thiadiazole from the thiosemi-
carbazide by the cyclization in sulphuric acid.
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4. Mei-Hsiu Shih and Cheng-Ling Wu468 have synthesised thiadiazole
derivatives by thecyclization of 3-aryl-4-formylsydnone thiosemicarbazones
with ferric chloride.
5. Jag Mohan et. al.469 have prepared thiadiazole derivatives by the cyclisation
of amino mercapto triazole and aryl aldehyde in presence of p-TsOH.
THERAPEUTIC IMPORTANCE
From the literature survey it was revealed that thiadiazole derivatives are
better therapeutic agents as shown under.
(a)  Antitumor470
(b)  Antibacterial471
(c)  Antiviral472
(d)  Antagonist agent473
(e)  Antitubercular474
(f)  Amoebicidal475
(g)  Algaecides and Antifouling476
(h)  Antiaflatoxigenic477
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(i) Antipyretic478
(j) Antischistosomal479
(k) CNS depressant480
(l) Pesticidal481
(m) Herbicidal482
(n) Hypoglycemic483
(o) Insecticidal484
A series of 2-(alkylaminoacyl) derivatives of 2-amino-1,3,4-thiadiazoles have
been prepared by Mazzone P. et. al.485 and subjected to biological screening which
showed a local anesthetic activity both in infiltration and trunkular tests. Pifferi G.
and co-workers486 have synthesized (E)-2-methyl-6-phenylimidazo[2,1-b]-1,3,4-
thiadiazole-5-carboxaldehyde dimethylaminoacetohydrazone and observed the
diuretic activity of this compound, evaluated in rats in a dosage range of 2.5, 10
and 40 mg/kg, was higher than that of the reference compounds hydrochlorothiazide
and furosemide.
Shanker K. et. al.487 have synthesised triazolothiadiazole derivatives and
screened for AChE inhibitory activity. El-Kashef H. A. and co-workers488 have
prepared imidazothiadiazole derivatives and screened for their cardiotonic activity
in isolated guinea pig atria. A series of 2-[1-oxo-2-(substitutedamino)ethylamino
and 2- or 3-(substitutedamino) propylamino]5-trifluoromethyl-1,3,4-thiadiazole was
synthesized and evaluated for their local anesthetic and antiarrhythmic activity by
El-Kashef H. A. et. al.489 Newer 2-(substituted acetamido)-5-aryl-1,3,4-thiadiazoles
(XIV) have been prepared and screened for LD50 and diuretic activity by Sanmati
K. Jain and P. Mishra.490
S
N N
NH C
O
CH2X
R
(XIV)
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J. M. Colacino et. al.491 have documented anti-influenza virus activity of
thiadiazoles. Acetazolamide (X) was reported as diuretic and antiglaucoma by Celine
Chazalete et. al.492 and as anticonvulsant by E. E. Chufan et. al.493 Vergne Fabrice
et. al.494 have synthesised 1,3,4-thiadiazole derivatives (XI) and screened for their
antiinflammatory, anticacer and anti AIDS activity. Fatemeh Soltani et. al.495
synthesised thiadiazoles and studied their antibacterial activity.
Andreani A. et. al.496 have showed significant antisecretory activity of 5-cyano
methyl-6-methylimidazo[2,1-b] thiadiazole in the isolated rabbit gastric glands assay.
Anticonvulsant activities of 5-[4-(benzoylamino)phenyl]-2 substituted amino-1,3,4-
thiadiazoles against pentylenetetrazole induced seizures in male and female
Albino Swiss mice have been investigated by Vidin A. and co-workers497.
Marina Kritsanida et. al.498 have investigated thiadiazoles as antiviral agent.
Bernard Masercel et. al.499 have synthesised 1,3,4-thiadiazoles possessing potent
carbonic anhydrase inhibitor properties and also prepared 5-valproylamido 1,3,4-
thiadiazole-2-sulfonamide useful as strong anticonvulsant.
Che, Chao et. al.500 have prepared thiadiazole derivatives showing
antifungal and plant growth regulating effect. Lisa M. Thomasco et. al.501 have
prepared 1,3,4-thiadiazole (XII) possessing potent antibacterial activity against
Gram positive and Gram negative organisms. Samir A. Carvalho and co workers502
have documented antitrypanosomal profile of 1,3,4-thiadiazole derivatives (XIII).
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SO2NH2H3CHNOC S
N N
CH3
N
Cl
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B. S. Holla and co-workers503 have prepared 1,3,4-thiadiazole derivatives
with a view to study their insecticidal property.  Alireza faroumadi et. al.504 have
synthesised 1,3,4-thiadiazoles and studied their leishmanicidal activity. Ishvarsinh
Rathod  and co-workers505 have synthesised N-(1,3,4-thiadiazolo-2-yl)-5-
(substituted)-2-amino-4,5-(disubstituted) thiophene-3-carboxylic acids (XIV) as
analgesics and  antiinflammatory agents. R. H. Udipi et. al.506 have synthesised
some new triazolo[1,3,4]-thiadiazole derivatives (XV) useful as antimicrobial,
analgesic and antiinflammatory agents.
CONTRIBUTION FROM OUR LABORATORY
Parikh et .  al .  have used substi tuted thiazolidinone507, substi tuted
benzthiazole and s-triazine508,509 4-pyridyl510 moieties at 5-position (Y) in 1,3,4-
thiadiazole ring system and at 2-position (X) was substituted by aryl, amino and s-
triazine.511 H. H. Parekh and co-workers have synthesised 1,3,4-thiadiazole having
dapson512,513 bis moiety at 5-position (Y) and benzalamino, benzoylamino and
sulphonamido514, aryl515 moiety substituted at 2-position (X). H. H. Parekh et.
al.516 have formulated some new thiadiazoles as biologically active agents. General
structure for above references are as under.
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Recently, thiadiazole derivatives as antiinflammatory agents (XVI) have been
suggested by B. Gopal Krishna and co-workers517. Antibacterial and surface  activity
of some new 1,3,4-thiadiazole derivatives have been tested by Refat El-Sayed.518 Silvia
Schenone and co-workers519 have synthesised new 2,4-disubstituted 1,3,4-thiadiazole
derivatives (XVII) which showed analgesic and antiinflammatory activity in vivo;
ulcerogenic action was also reported.
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In view of the pronounced biological activities of triazoles and 1,3,4-
thiadiazoles, the synthesis of new derivatives which contain above mentioned
pharmacologically active nuclei have been undertaken. A comparative study for
synthesis of dihydro 1,3,4-thiadiazole using conventional method and microwave
irradiation has been made in order to study the rate of reaction period and yield
which have been described as under.
SECTION-I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-
HYDROXYPHENYL)-5 ,6 -DIHYDRO-6-ARYL-[1 ,2 ,4 ] -
TRIAZOLO[3,4-b][1,3,4]-THIADIAZOLES BY CONVENTIONAL
METHOD
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-
HYDROXYPHENYL)-5 ,6 -DIHYDRO-6-ARYL-[1 ,2 ,4 ] -
TRIAZOLO[3,4-b][1,3,4]-THIADIAZOLES BY MICROWAVE
METHOD
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3 - ( p - HY D R O X Y
P H E N Y L ) - 5 , 6 - D I H Y D R O - 6 - A RY L - [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b] [1,3,4]-
THIADIAZOLES BY CONVENTIONAL METHOD
Dihydrothiadiazoles play a vital role owing of their wide range of
pharmacological activity. With a view to getting better therapeutic agents and to
evaluate it’s pharmacological profile, different type of dihydrothiadiazole
derivatives of type (XI) have been prepared by the condensation of 3-mercapto-
4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole with different aromatic aldehydes in
presence of p-toluenesulphonic acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been
checked by thin layer chromatography.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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N
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S
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R
Type (X)     R = Aryl
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-(p-HYDROXY PHENYL)-5,6-DIHYDRO-6-(p-ANISYL)-
[1 ,2 ,4 ] -TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2931 2975-2950 520
-CH3 C-H str. (sym.) 2858 2880-2860   “
C-H i.p.def. (asym.) 1474 1470-1435   “
C-H o.o.p. def. (sym.) 1357 1390-1370   “
Aromatic C-H  str. 3091 3080-3030 521
C=C str. 1564 1585-1480   “
C-H i.p. def. 1108 1125-1090   “
C-H o.o.p. def   828     835-810   “
Triazole C=N str. 1600 1612-1593 520
moiety C-N str. 1022 1220-1020 525
N-N str. 1022 1050-1010 520
                     (overlapped)
O-H str. 3440 3550-3200 525
O-H bending 1422 1420-1330                “
Thiadiazole N-H str. 3440 3450-3200 520
                                           (overlapped)
N-H def. 1600 1650-1580   “
                                           (overlapped)
C-S-C str.   677                    720-570 521
Ether C-O-C str. (asym.) 1265 1275-1200 520
C-O-C str. (sym.) 1022 1075-1020   “
                                        (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
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Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (300 MHz)
PMR SPECTRAL STUDY OF 3-(p-HYDROXYPHENYL)-5,6-DIHYDRO-6-(3,4-
DIMETHOXYPHENYL)- [1 ,2 ,4 ] -TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
Signal
  No.
Signal Position
    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.92 3H singlet Ar-OCH3                     -
2. 3.95 3H singlet Ar-OCH3         -
3. 6.88-6.91 2H doublet Ar-Haa’ Jab=8.74
4. 6.96-6.99 1H doublet Ar-He Jed=8.21
5. 7.37-7.40 1H double Ar-Hd Jdc=1.88
doublet Jde=8.50
6. 7.50-7.51 1H doublet Ar-Hc Jcd=1.83
7. 7.77-7.80 2H doublet Ar-Hbb’ Jba=8.75
8. 9.46 1H singlet -OH         -
9. 9.76 1H singlet -CHf         -
N N
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N
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S
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f
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EXPANDED AROMATIC REGION
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-(p-H Y D R O X Y
P H E N Y L ) - 5 , 6 - D I H Y D R O - 6 - A RY L - [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b][1,3,4]-
THIADIAZOLES BY MICROWAVE METHOD
As a part of our research programme towards the non traditinal approach to
the experimental set up of organic reactions, the concept of “Microwave induced
Organic Reaction Enhancement” (MORE) chemistry has been utilised for rapid
and efficient synthesis of some dihydrothiadiazoles which is described as under.
The synthesis was carried out by irradiating condensation of 3-Mercapto-4,N-amino-
5-p-hydroxyphenyl-1,2,4-triazole with different aromatic aldehydes in the presence
of p-toluenesulphonic acid.
Various preparations of the dihydrothiadiazoles by microwave irradiations
are available in literature.492-497
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all compounds have been checked
by thin layer chromatography.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation
source and data are compared in terms of yield and reaction period have been cited
in Table No. 11a.
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R
N N
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DMF
microwave irradiation 
8-10 mins.
Type (XI)    R = Aryl
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TABLE NO. 11a   :  COMPARISION OF CONVENTIONAL METHOD AND
MICROWAVE INDUCED SYNTHESIS OF 3-(p-HYDROXY
PHENYL)-5,6-DIHYDRO-6-ARYL-[1,2,4]-TRIAZOLO
[3,4-b][1,3,4]-THIADIAZOLES
Comp.
  No.
R Thermal Microwave M. P.
 oCReaction
Period (hrs.)
Yield
  %
Reaction
Period (min.)
  11a C6H5- 10 56   8 68 163
11b 2-Cl-C6H4- 13 63 10 75 186
11c 4-Cl-C6H4- 12 70   9 82 198
11d 3-Br-C6H4- 14 54   8 67 143
11e 4-OCH3-C6H4- 12 58   9 70 204
11f 3,4-(OCH3)2-C6H3- 11 48   8 65 230
11g 4-CH3-C6H4- 12 62   8 77 172
11h 2-OH-C6H4- 13 68 12 84 180
11i 4-OH-C6H4- 10 59 10 78     > 300
11j 2-NO2-C6H4- 12 65 10 76 245
11k 4-NO2-C6H4- 12 72   8 89 220
11l 2-C5H4N- 13 60   8 74 235
Yield
  %
CONCLUSION
We have demonstrated a rapid and general synthesis of 1,3,4-dihydro
thiadiazoles using a variety of aromatic aldehydes with heating in a microwave
oven which can be considered as a step towards Green Chemistry. Consequently,
reactions exhibit cleaner products and more facile work-up procedures. The method
affords high yields of the desired products in remarkably short reaction times
decreased to 8-10 min. from 10-14 hrs. and improve reproducibility. The reaction
conditions are sufficiently mild to be employed for the construction of the
heterocyclic thiadiazole system and suitable for high throughput synthesis of the
compounds.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3 - ( p - H Y D R O X Y
P H E N Y L ) - 5 , 6 - D I H Y D R O - 6 - A RY L - [ 1 , 2 , 4 ] - TRIAZOLO[3,4-b][1,3,4]-
THIADIAZOLES
(A) Synthesis of Potassium p-hydroxybenzoyl dithiocarbamate
See [B] Part-I, Section-I (C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole
See [B] Part-I, Section-I (D).
SECTION-I
(A) Synthesis of 3-(p-hydroxyphenyl)-5,6-dihydro-6-(p-anisyl)-[1,2,4]-triazolo
[3,4-b][1,3,4]-thiadiazole by conventional method.
A mixture of 3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole (2.08
g, 0.01 M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene
sulphonic acid (50 mg) was refluxed for 12 hrs. The reaction mixture was poured
onto crushed ice. The product was isolated and crystallised from ethanol. Yield
58%, m.p. 204oC, (C16H14N4O2S : Required : C, 58.88; H, 4.32; N, 17.17; Found
: C, 58.82; H, 4.27; N, 17.12%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
Similarly  other derivatives were synthesised. The physical data are recorded
in Table No. 11.
(B) Antimicrobial activity of 3-(p-hydroxyphenyl)-5,6-dihydro-6-aryl-[1,2,4]-
triazolo-[3,4-b][1,3,4]-thiadiazoles.
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (D).
The zone of inhibition of test solutions are recorded in Graphical Chart No. 11.
203Thiadiazole...
Antitubercular screening of the compounds of type (X) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described in [A] Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are recorded in
Table No. 11b.
SECTION - II
(A) Synthesis of 3-(p-hydroxyphenyl)-5,6-dihydro-6-(p-anisyl)-[1,2,4]-
triazolo[3,4-b][1,3,4]-thiadiazoles by microwave method.
A mixture of 3-mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole (2.08 g,
0.01 M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene sulphonic
acid (50 mg) was irradiated in a microwave oven for 8-10 min at 280 watts. The
contents were cooled and poured onto crushed ice. The product was isolated and
crystallised from ethanol. Yield 70%, m.p. 204oC.
Similarly other derivatives have been synthesised.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that all the thiadiazoles
of type (XI) were mild to moderately active against different strains of Gram positive
and Gram negative bacteria.
Maximum activity was observed in compounds bearing R=3-bromophenyl
against B.coccus and S.aureus. The significant activity was observed in compounds
bearing R=2-chlorophenyl, 3-bromophenyl and 2-pyridyl against E.aerogenes and
P.aeruginosa.
ANTIFUNGAL ACTIVITY
All the compounds exhibited mild activi ty against  A.niger except
compounds bearing R=4-bromophenyl which showed good activity against
A.niger.
The antibacterial activity was compared with standard drugs viz.Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug viz. Greseofulvin.
ANTITUBERCULAR ACTIVITY
Almost all compounds were found to be less active against Mycobacterium
tuberculosis H37Rv except 4-methylphenyl.
The antitubercular activity data have been compared with standard drug
Rifampin.
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TABLE NO. 11b : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
N N
N
N
H
S
OH R
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID Comment
Assay
295789 VKS-13 4-OCH3-C6H4- Alamar H37Rv >6.25 7 -          MIC Rifampin =
           0.25 mg/ml
          @ 98% Inhibition
295790 VKS-14 2-Cl-C6H4- Alamar H37Rv >6.25 0 - "
295791 VKS-15 2-OH-C6H4- Alamar H37Rv >6.25 0 - "
295792 VKS-16 C6H5- Alamar H37Rv >6.25 0 - "
295793 VKS-17 4-Cl-C6H4- Alamar H37Rv >6.25 25 - "
295794 VKS-18 3-Br-C6H4- Alamar H37Rv >6.25 14 - "
295795 VKS-19 2-NO2-C6H4- Alamar H37Rv >6.25 0 - "
295796 VKS-20 3,4-(OCH3)-C6H3- Alamar H37Rv >6.25 10 - "
295797 VKS-21 4-CH3-C6H4- Alamar H37Rv >6.25 37 - "
295798 VKS-22 3-NO2--C6H4- Alamar H37Rv >6.25 0 - "
295799 VKS-23 C5H4N- Alamar H37Rv >6.25 3 - "
295800 VKS-24 4-OH-C6H4- Alamar H37Rv >6.25 0 - "
MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
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